

Review articles

Mesenchymal stem cells in lung diseases and their potential use in COVID-19 ARDS: A systematized review



Bruna Benigna Sales Armstrong^a, Juan Carlos Montano Pedrosa^b,
José da Conceição Carvalho Jr.^b, Lydia Masako Ferreira^{b,*}

^a Universidade Federal do Piauí (UFPI), Terezina, PI, Brazil

^b Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil

HIGHLIGHTS

- None of the analyzed studies related serious adverse effects or toxicity to IV ASCs administration.
- This review suggests optimism in IV ASCs for lung damage in severe COVID-19 ARDS.
- Further studies on IV ASCs in COVID-19 are needed for standard dosage.

ARTICLE INFO

Keywords:

Mesenchymal stem cells
COVID-19
Lung disease

ABSTRACT

COVID-19 can converge with the pro-inflammatory immunoregulatory mechanisms of chronic lung diseases. Given the disorders inherent to lung transplantation and the inexistence of other definitive therapeutic alternatives, Adipose tissue-derived Stem Cells (ASCs) presented themselves as a therapeutic hope. The purpose of this review is to assess the basis for the potential use of ASCs in lung diseases unresponsive to conventional therapy, relating to their possible use in COVID-19 ARDS. 35 studies comprised this review, 14 being narrative reviews, 19 preclinical trials and two proofs of concept. COVID-19 can converge with the pro-inflammatory immunoregulatory mechanisms of chronic lung diseases. In view of the disorders inherent to lung transplantation and the inexistence of definitive therapeutic alternatives, Adipose tissue-derived Stem Cells (ASCs) presented themselves as a therapeutic hope. Its detailed reading indicated the absence of serious adverse effects and toxicity to the administration of ASCs and suggested possible effectiveness in reducing lung damage, in addition to promoting the recovery of leukocytes and lymphocytes with its immunomodulatory and anti-apoptotic effects. The revised clinical data suggests optimism in the applicability of ASCs in other immunoinflammatory diseases and in severe COVID-19 ARDS. However, further studies are needed to develop a consensus on the methods of collection of ASCs, the ideal dosage schedule, the most effective time and route of administration, as well as on the definition of indications for the administration of ASCs in cases of COVID-19 for conducting clinical trials in near future.

Introduction

The end of 2019 was marked by the growing number of cases of severe respiratory illnesses of unknown origin in Wuhan, China; in January 2020, its etiologic agent, the contagious Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) was identified [1]. Two months later, in March 2020, the World Health Organization (WHO) elevated a category of the 2019 Coronavirus Disease (COVID-19) from epidemic to the first pandemic caused by coronavirus, which on March 2, 2021 already illustrated a scenario with 2.6 million new confirmed and an increase of 63,000 deaths in the last week [2].

SARS-CoV-2 is one of three coronaviruses that evolve with Acute Respiratory Distress Syndrome (ARDS) [3]. Despite the genomic similarity of 79% to the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and 50% to the Middle East Respiratory Syndrome coronavirus (MERS-CoV), SARS-CoV-2 does not stand out for its relatively low 6.76% mortality, compared to 9.6% for SARS-CoV and 35.5% for MERS-CoV, but rather due to its high infectivity, which underscores the superiority of absolute numbers over percentage data [4].

Despite different etiologies, the pathophysiology of COVID-19 may converge to the same pro-inflammatory immunoregulators of chronic lung diseases: [3] abnormal repair processes with concomitant destruction of airway epithelium [5] and vascular endothelium [6]. However, regardless

*Corresponding author.

E-mail address: lydiamferreira@gmail.com (L.M. Ferreira).

<https://doi.org/10.1016/j.clinsp.2023.100237>

Received 21 April 2022; Revised 23 January 2023; Accepted 24 April 2023

of the steady growth in the prevalence of asthma and Chronic Obstructive Pulmonary Disease (COPD) in recent years as well as COPD ranking third among the causes of chronic disease mortality worldwide, lung transplantation is still the only curative therapy for chronic lung disorders [1].

Due to the lack of other definitive therapeutic alternatives for chronic lung diseases and the disorders inherent to lung transplantation – high donor incompatibility, lifelong need for immunosuppressive therapy, and high mortality rate after the procedure (50% in 5 years)[1] – Preclinical and clinical studies of Mesenchymal Stem Cells (MSCs), with their paracrine immunomodulatory mechanisms that reduce pulmonary inflammation and promote tissue repair, have raised expectations about this possibility of treatment for chronic lung disease [1,7].

Even though, since their first description in 1968 [8], the number of clinical trials using MSCs in the management of lung diseases was somewhat unimpressive until this year, when the SARS-CoV-2 pandemic led to the pursuit of possible effective treatments, as of March 9, 2021, of the 110 studies registered in the National Institutes of Health (NIH) Clinical Trial Database on the use of cell therapy in lung diseases, 72 are specifically for COVID-19, with new studies being registered daily [9,10].

Adipose Tissue (TA) MSCs have received increasing attention over the years, both for their practical collection using local anesthesia [11], and for the greater quantity and easy isolation of target stem cells compared to those originating from Bone Marrow (BM) [11]. As one of the cellular components of the stromal Vascular Fraction (FVE), the portion of subcutaneous fat, it can be easily isolated by enzymatic degradation of adipocytes and cell expansion [11].

Although the analysis of experimental studies by Wecht and Rojas [12] has suggested both efficacy – reducing inflammation, preventing the progression of fibrosis, and accelerating tissue repair – and safety in the use of MSCs in chronic lung diseases, the effects of ASCs are underreported. Therefore, the objective of this study is to evaluate, through a systematic review of the literature, the therapeutic rationale of ASCs in chronic or acute pulmonary diseases that are unresponsive to conventional therapy, relating to their possible use in ARDS by COVID-19.

Method

General information

The present study is a systematized review of the literature. Systematized review is a classification described in the literature that attempts to include elements from the systematic review process to the narrative review while maintaining greater freedom in the quality assessment and comprehensive searching, all of which are shown in their limitations of methodology. To this end, the present article used an adaptation of the PRISMA guidelines suitable for systematized reviews.

The following databases were searched:

- CENTRAL (Cochrane Library) - <https://www.cochranelibrary.com/>
- CLINICAL TRIALS - <https://clinicaltrials.gov>
- LILACS (BIREME) - <http://brasil.bvs.br/>
- MEDLINE (PubMed) - <https://www.ncbi.nlm.nih.gov/pubmed/>
- SCOPUS - <https://www.scopus.com>
- WEB OF SCIENCE - <https://www.webofscience.com>

gray literature was also searched: <http://www.opengrey.eu/> and <https://www.worldcat.org/>.

The descriptors (DeCS/MeSH) selected, in Portuguese and English, were: mesenchymal stem cells (células tronco mesenquimais), pneumonia (broncopneumonia) and pulmonary fibrosis (fibrose pulmonar).

Search strategies

1 - ((pulmonary fibrosis[MeSH Terms]) OR (fibrose pulmonar [DeCS Terms]) OR (pneumonia[MeSH Terms]) OR (broncopneumonia[DeCS

Terms])) AND ((mesenchymal stem cells[MeSH Terms]) OR (células tronco mesenquimais [DeCS Terms]))

2 - Articles referenced by the works filtered from the search strategy that covered the eligibility criteria were also added.

Selection process according to the inclusion and exclusion criteria

Publications were selected using the search strategy previously described, without date or language limitation. Duplicates and titles not related to the topic were excluded before the screening.

The inclusion criteria choice was based on the PICO strategy. The study population included lung diseases, the intervention analyzed was the infusion of mesenchymal stem cells derived from adipose tissue, which was compared to conventional treatment or placebo saline infusion and analyzed for efficacy and safety.

In the first selection process abstracts were reviewed for the following inclusion criteria: (a) Administration of Intravenous (IV) ASCs, which (b) Were not used as a concurrent vehicle for other therapeutic agents, as (c) Treatment for acute or chronic lung diseases.

The second selection process excluded: a) Editorials, comments, and letters to the editor, in addition to articles that b) Discussed exclusively non-adipose stem cells and derivatives, or that c) Did not involve the intravenous administration of ASCs in d) Pulmonary immunoinflammatory diseases.

Endpoints

The evaluated outcomes can be divided according to two main approaches: efficacy and safety. The primary endpoint of the efficacy assessment was clinical parameters, while the primary endpoints of the safety assessment were descriptions of serious adverse events and death correlated to the intravenous administration of ASCs. Secondary outcomes included: a) For efficacy – analysis of the homing capacity of ASCs, serial imaging tests, histopathology, cytology, biochemistry, TUNEL method, PCRs, and immunohistochemistry, in addition to taking into account the study design, its participants, the origin of ASCs and dosage administered for comparative purposes; as well as b) Safety – mild adverse effects (transient fever, diarrhea, bronchitis and common colds) secondary to the IV infusion of ASCs.

Results

After inserting the search strategy in databases, 2077 results were obtained, among which 1046 studies were initially excluded, then, based on the reading of titles and abstracts before the screening, only 231 articles were pre-selected (Fig. 1). After evaluating the full text according to the eligibility criteria already described, 36 studies composed this review, being: 14 narrative reviews, 19 preclinical trials and three clinical trials. The clinical characteristics of these studies are summarized in Tables 1, 2 and 3.

The search in the clinical trials database resulted in 29 studies of adipose-derived stem cells in lung diseases, their official status being: one no longer available, five unknown, five withdrawn, one enrolling by invitation, four recruiting, four not yet recruiting, one suspended, two terminated, six completed. No study has published its results in academic journals in the literature to date. The population, intervention, comparator and outcome of these studies are summarized in Table 4.

Searching the gray literature did not present results contemplated by the subject of the study.

Discussion

Although the mechanisms by which ASCs reduce lung inflammation and promote tissue repair are not fully elucidated [3], the use of mesenchymal stem cells in acute lung diseases had previously been reviewed by current literature showing promising results [13]. Since the initial




Fig. 1. Flowchart of the selection process for researched articles. Legend: After inserting the search strategy in the databases, 2077 results were obtained, among which 1846 studies were initially excluded and only 231 articles were pre-selected, based on the reading of titles and abstracts. After evaluating the full text according to the eligibility criteria already described, 36 studies composed this review, being: 14 narrative reviews, 19 preclinical trials and three proofs of concept (N, Number).

analysis of the new disease caused by SARS-CoV-2 demonstrated main pathologic features similar to ALI/ARDS [14], the hypothesis of transposing these benefits in the context of a new pandemic without known therapeutic options were naturally investigated [1,3,14]. However, upon closer analysis, peculiarities were found in the pathophysiology of COVID-19 that benefited from autologous or allogeneic IV ASCs in a different way than those initially imagined [3].

In this context the present study proposed to analyze the benefits of cell therapy in COVID-19, exposing the possible common path among chronic and acute lung diseases that allow COVID-19 to manifest itself like chronic lung diseases [1,6], with fibrosis and pulmonary consolidation, but with an acute and fulminant evolution [6], owing to inflammatory exudation, pulmonary edema, and inflammatory cytokine storm.

Thus, the effectiveness evidenced by Liu et al. [3], Siu et al. [15], and other studies is here revised as being due to immune dysregulation and fibrosis being common components of the pathophysiology of chronic and acute lung diseases, being closely related to their morbidity and mortality despite the different etiologies [7,13]. This convergence differs from a physiological immune response by inflammation resulting from both the activation of native pulmonary macrophages, molecular patterns associated with pathogens or associated damage, and the overproduction of alarmins that attract circulating immune cells to the lungs, initiating inflammation secondary to trauma and hypersensitivity [16,17].

Regarding clinical parameters, the present review is in line with similar studies by showing that IV administration of ASCs: has pulmonary homing, rescued the suppressive effects of cigarette smoke on bone marrow hematopoietic progenitor cell function [18], restored sustained weight loss [8,18,19], reduced PF score [8,19], increased survival in animal models improved the PF Ashcroft score [8,19], attenuated pulmonary edema [18,20], preserved pulmonary architecture [8,19,21,22,23], reduced allergic symptoms and mucus production [20,22], in addition to exerting protective effects on ALI secondary to pulmonary infection by *P. aeruginosa* [24,25,26].

In opposition to the study by Feizpour et al. [27], the histopathological endpoints showed that ASC IV, not only reduced inflammatory infiltration [28–31], decreased lung cell death [19,31–34] and increased air space [35,36], but also attenuated the increase in inflammatory cells [28–31] and presented tissue regenerative potential [31–33].

These findings are most likely due to the remodeling capacity of the microenvironment exhibited by ASCs IV [31,37,38] through antioxidant and anti-apoptotic properties by inhibiting IL-4, IL-5, and IL-13 from the Th2 pathway concomitant with the increase in Th1 cytokines [11,12,31,37,38]. Furthermore, ASCs decreased levels of TGF- β , collagen I fibers, apoptotic cells, plasma fibrinogen, PDGF, Von Willebrand factor, NOS-2, FGF7, CC16, CK19, myeloperoxidase, MIP-2 and proteins totals in BALF [13,18–22,39] as well as inhibited: total immune cells, NET formation, fibroblast activation, collagen deposition, epithelial-mesenchymal transition, bacterial loads, iNOS, NF κ B and Caspase-3 expression; in addition to significantly increasing the Bcl-2/Bax ratio [24–28,30,35,40–42].

Unlike similar studies that did not review the dosing regimen used, nor its effect on the studied endpoints, the present systematic review suggests that the fastest dose-dependent effect was exerted by cells cryopreserved at the primary site of infection [27] and the high dose showed not only a greater decrease in these parameters but also a low expression of α SMA and reversal of induced histopathological changes [26,43,44].

Therefore, and in accordance with other similar studies, this review suggests: the safety of IV ASCs [39,43–45] [31,39,43–45], based on the absence of serious adverse effects or toxicity to their administration, and the applicability of ASCs in ALIs of different pathophysiological mechanisms [5,6,14,20,23,28,29,31,37–39], including severe COVID-19 [1,6,26,40,43]. The physiological rationale reviewed suggests that therapy with ASCs can reduce lung damage in a patient with ARDS from SARS-CoV-2 infection, in addition to promoting leukocyte and lymphocyte recovery with its immunomodulatory and anti-apoptotic effects [12,17,26,40,43].

Table 1

Narrative reviews on the administration of ASCs in chronic or acute lung diseases.

Authors	Pathology	Effectiveness analysis Study method	Participants	Intervention	Results observed	Safety analysis Serious adverse events	Light adverse events
Barczyk et al. 2015	IPF	• Narrative review • NR number of tests used in its preparation (16 in the table in the article exclusively about 1 of the 5 models of pulmonary fibrosis induction and 2 clinical tests in humans/ presented 159 references in all) • NR number of articles with ASCs (2 present in the table on pulmonary fibrosis induced by BLM and also presents 4 references that directly cite ASCs) • Analysis of histopathology, biochemistry and immunohistochemistry • Stem cell markers: (+) CD44, CD29, CD105 and CD90 and (-) CD45 and CD34	Mices	• Tzouveleakis: autologous • Lee: xerogenic • Administration IV and EB • Tzouveleakis: 0.5×10^6/Kg, 3 doses with monthly intervals • Lee: 4 doses of 1×10^6 applied concurrently with BLM	Cell therapy for IPF appears to be overestimated based on currently available information.	None on IV infusion of ASCs. Tzouveleakis: Worsening of dyspnea: $n = 2$ (14%). Oxygen desaturation: $n = 2$ (14%).	Transient fever tzouveleakis: Fever: $n = 7$ (50%). Cough worsening; $n = 2$ (14%).
Strour e Thébaud 2015	BLM-induced pulmonary fibrosis (PF)	• Narrative review • 17 studies used in its preparation • 2 articles with ASCs (but only one IV) • Analysis of histopathology, collagen deposition, mortality, Aschcott score and inflammatory markers: TGF-β, TNF-α, IFN-γ, IL6, IL1, MMP2, MMP9, MMP13 • The review does not describe the stem cell markers of the reviewed studies (CD)	Mices	• Culture-expanded human adipose-derived xerogenic MSCs • Dose: 0.3×10^6 cells/kg IV (4 doses in weeks 8, 10, 12, and 14)	MSC therapy was effective in animal models of BLM-induced lung injury. Most studies examined the early inflammatory phase providing a better representation of acute disease exacerbations.	None	Transient Fever
Stabler et al. 2015	Chronic lung diseases (ARDS, asthma and exposure to cigarette smoke)	• Narrative review • 20 studies used in its preparation • 3 articles with ASCs (3 pre-clinical and 1 clinical) • Analysis of the ability to differentiate clinical effects, anti-inflammatory effects and safety • The review does not describe the stem cell markers of the reviewed studies (CD)	Guinea pigs and felines; ARDS patients	• Culture-expanded adipose-derived allogeneic MSCs • Zheng: 1×10^5 cell/kg IV (DU) • Preclinical: NR dosage	MSC-based therapies were effective and phase 1 clinical trials proved the safety of MSC therapy in ARDS, asthma, and exposure to cigarette smoke.	None	None
Geiger et al. 2017a	FPI; Acute respiratory distress syndrome, Chronic obstructive pulmonary disease	• Narrative review • 24 tests (clinical and pre-clinical) • 3 tests with ASCs (2 clinical and 1 pre-clinical) • Analysis of lung function and safety • The review does not describe the stem cell markers of the reviewed studies (CD)	NR	• Allogeneic and autologous MSCs derived from adipose tissue, expanded by culture • Administered intravenously and EB • Phase I: 1×10^6 cell/kg • Phase Ib: 5×10^5 MSC/kg-1 • Pre-clinical: 40×10^6 MSCs/kg-1 • NR number of doses	MSC-based therapies for pulmonary diseases present themselves as potential viable treatment options for clinical application. In particular, the potential of genetically modified MSCs, which allows for a considerable increase in therapeutic activity.	NR (Not reported)	NR

(continued on next page)

Table 1 (Continued)

Authors	Pathology	Effectiveness analysis Study method	Participants	Intervention	Results observed	Safety analysis Serious adverse events	Light adverse events
Antoniou et al. 2018	FPI; ARDS, COPD, severe emphysema, advanced pulmonary sarcoidosis	• Narrative review • 8 clinical tests • 2 tests with ASCs • Analysis of pulmonary inflammation markers in IV administration • The review does not describe the stem cell markers of the reviewed studies (CD)	Patients with ARDS	• Adipose tissue-derived, culture-expanded allogeneic MSCs • Administered via IV and EB • Single dose of 1×10^6 cell./kg	Recent clinical studies of the administration of autologous or allogeneic MSCs in patients with various lung diseases provide adequate evidence for the safety of using MSCs in these patient groups	NR (Not reported)	None
Harrell et al. 2019	Immunoinflammatory lung diseases (ARDS, pneumonia, asthma, COPD, IPF)	• Narrative review • NR number of studies used in its preparation, but presented 119 references • 4 articles with ASCs (1 clinician and 1 preclinical) • Analysis of markers of lung inflammation, improvement in quality of life, lung function and safety • The review does not describe the stem cell markers of the reviewed studies (CD)	NR	• MSCs (does not say whether autologous or allogeneic) derived from adipose tissue, placenta, umbilical cord and culture-expanded bone marrow • Zheng: 1×10^6 cell./kg IV (DU) • Other ASCs: NR	The reviewed clinical trials suggest that the administration of MSCs was well tolerated and that MSC-based therapy is a safe therapeutic approach, as only a limited number of side effects have been reported.	None	Bronchitis and common cold were the most frequent
Zanoni et al. 2019	Radiation-induced lung injury (LP)	• Narrative review • NR total number of studies used in its preparation (has 203 references) • NR number of articles with ASCs (12 references cite ASCs directly) • Analysis of histopathology, biochemistry and immunohistochemistry • Stem cell markers: (+): CD105 (endoglin, SH2), CD73 (ecto-50-nucleotidase) and CD90 (Thy1) (-): CD45, CD19 or CD79, CD14 or CD11b, and HLA-DR....	Humans and Mices	• NR origin (auto, alo, xero) of adipose stem cells • Administration IV and EB • NR dose	The lack of standardized methods for collecting MSCs and little or no information available on optimal dosage, timing and route of administration make it difficult to imagine the use of MSC-based therapy in clinical practice in the near future.	NR (Not reported)	NR
Behnke et al. 2020	Bronchopulmonary dysplasia, Asthma, acute lung injuries (systemic and infectious), Chronic obstructive pulmonary disease (COPD)	• Narrative review • 75 studies used in its preparation • 12 articles with ASCs [only 8 IVs: 1 from asthma, 1 from ALI, 1 from COPD, 3 from BLM, 2 from cigarette smoke (1 of them smoke or elastase) and 1 elastase (compare IV with IT)] • Analysis of histopathology, biochemistry and immunohistochemistry • The review does not describe the stem cell markers of the reviewed studies (CD)	Humans and Mices	ORIGIN ADIPOSE STEM CELL PRE CLINICOS: • Cigarette smoke: (human $\times$ rat, human) • Elastase: mouse • Asthma: human • ALI: Humans • COPD: human • BLM: mices PRECLINICAL DOSE: • Cigarette smoke: 1 study used 3×10^5 in 4 doses (weeks 8, 10, 12 and 14) and the other used 1×10^5 DU • Elastase: 1×10^5 DU • Asthma: 1×10^5 DU • ALI: 1×10^6 DU • COPD: 1×10^6 DU • BLM: 2 studies used 5×10^5 DU / and 1 study used 4×10^7 in 3 doses (days 3, 6 and 9)	The preclinical results raise high hopes that MSC-based therapies will successfully lead to cures rather than just relief of disease symptoms. Available data from clinical trials have proven the safety of such an age- and disease-entity approach.	In preclinical reports, there was death from DIC and cardiac and respiratory dysfunction due to the infusion of high doses of MSCs.	None

(continued on next page)

Table 1 (Continued)

Authors	Pathology	Effectiveness analysis Study method	Participants	Intervention	Results observed	Safety analysis Serious adverse events	Light adverse events
Cruz e Rocco 2020b	Chronic lung diseases (Asthma, COPD, Idiopathic pulmonary fibrosis-IPF, PAH, silicosis)	• Narrative review • NR total number of studies used in its preparation (it has 99 references) • NR number of articles with ASCs (10 references cite ASCs directly) • Analysis of histopathology, biochemistry and immunohistochemistry • Stem cell markers: (+) CD105, CD73, and CD90 and (-) CD45, CD34, CD14 or CD11b, CD79 alpha, or CD19, and HLA-DR....	Humans and Mices	CLINIC • NR dose, neither if it was autologous or allogeneic. • NR origin (auto, alo, xero) of adipose stem cells • Administration IV • NR dose	MSC-based therapy is a promising alternative for the treatment of chronic lung diseases. Preclinical studies with MSCs generated great enthusiasm for their therapeutic potential in these conditions. Early clinical trials demonstrated that MSC administration is safe, with few adverse effects	None	None
Ntolios et al. 2020	IPF	• Narrative review • 9 clinical tests • 3 tests with ASCs (12, 15, 60 pcts) • Clinical and radiological analysis • Safety and laboratory analysis of inflammatory markers: C-reactive protein, LDH, D-dimer and ferritin • Stem cell markers (+): CD105, CD73, CD90, CD44, CD71, Stro1, CD106 (VCAM-1), CD166 (ALCAM), ICAM-1, CD29; and (-): CD45, CD34, CD11, CD80, CD86, CD40, CD31 (PECAM-1), CD18, CD56, HLA II	Patients with mild to moderate IPF	• Allogeneic MSCs derived from adipose tissue, placenta and culture-expanded bone marrow • Administered intravenously and endobronchial • 1 Phase I: 1×10^6 cells/kg IV (DU) • 2 Phase Ib: 5×10^5 cell./kg EB (3 doses 1 month apart)	Clinical trials currently completed suggest that cell therapies are safe and can be effective	None	Phase Ib EB: minor adverse effects, mainly related to bronchoscopy.
Qin e Zhao 2020	ARDS and COVID-19	• Narrative review • 18 tests (clinical and pre-clinical) • 2 tests with ASCs (1 clinician and 1 pre-clinical) • Analysis of markers of lung inflammation, onset of antimicrobial response, protective effects, decrease in damage to distal organs • The review does not describe the stem cell markers of the reviewed studies (CD)	NR	• MSCs (does not say whether autologous or allogeneic) derived from adipose tissue, placenta and culture-expanded bone marrow • Clinical: 1×10^6 cells/kg IV (DU) • Pre-clinical: NR	The safety of MSC therapy has been demonstrated in early-stage clinical trials with a small number of patients. Systemic administration of MSC proved to be effective.	None	None
Rogers et al. 2020a	ARDS and COVID-19	• Narrative review • NR total number of studies used in its preparation • NR number of articles with ASCs • Analysis of histopathology, biochemistry and immunohistochemistry • The review does not describe the stem cell markers of the reviewed studies (CD)	Mices and humans	• NR reported dose REFERRED DOSE: • Perlee: 4×10^6 ASCs/kg (NR number of doses) • Zheng: 1×10^6 DU	Cell-based therapies have demonstrated safety in human clinical trials, warranting further investigation	None	Transient Fever

(continued on next page)

Table 1 (Continued)

Authors	Pathology	Effectiveness analysis Study method	Participants	Intervention	Results observed	Safety analysis Serious adverse events	Light adverse events
Yen et al. 2020b	Immunoinflammatory lung diseases (ARDS, COPD, IPF...)	• Narrative review • 68 clinical trials • 12 tests with ASCs • Does not report the analysis parameters of the results • The review does not describe the stem cell markers of the reviewed studies (CD)	NR	• Allogeneic and autologous MSCs derived from adipose tissue, expanded by culture • Does not report via Administration • Does not report dose schedule	MSC for COVID-19 should be targeted to very severe cases where ARDS and an exuberant immune response are observed. Preclinical MSC data were quite consistent, and MSC clinical data in other immunoinflammatory diseases support the relative safety of MSC therapy, even though the efficacy may be more difficult to interpret.	NR (Not reported)	NR
Xiao et al. 2020	ARDS and COVID-19	• Narrative review • NR number of studies used in its preparation, but presented 48 references • 1 articles with ASCs (clinical) • Analysis of markers of lung inflammation, clinical improvement and safety • The review does not describe the stem cell markers of the reviewed studies (CD)	Patients with ARDS	• MSCs (does not say whether autologous or allogeneic) derived from adipose tissue, menstrual blood, umbilical cord and culture-expanded bone marrow • Zheng: 1×10^6 cell/kg IV (DU)	Safety and possible efficacy have been demonstrated in some patients with ARDS. Although some progress has been made, there is insufficient clinical evidence to prove the efficacy of MSCs in treating ARDS.	None	None

COVID-19, 2019 Coronavirus Disease; ARDS, Acute Respiratory Distress Syndrome; COPD, Chronic Obstructive Pulmonary Disease; IPF, Idiopathic Pulmonary Fibrosis; PAH, Pulmonary Arterial Hypertension; PF, Pulmonary Fibrosis; BLM, Bleomycin; LP, Lung Lesion; NR, Does Not Refer; ASCs, Adipose tissue-derived Stem Cells; TGF- β , Transforming Growth Factor beta; TNF- α , Tumor Necrosis Factors Alpha; IFN- γ , Interferon-gamma; IL, Interleukin; MMP, Metalloproteinases; IV, Intravenous; IT, Intratracheal; EB, Endobronchial; DU, Single Dose; kg, Kilogram; MSC, Mesenchymal Stem Cells; CD, Differentiation Cluster; cell., Cells.

Table 2
Preclinical trials on the administration of ASCs in chronic or acute lung diseases.

Authors	Pathology	Effectiveness analysis Study method	Participants	Intervention	Follow-up	Results observed	Safety analysis Serious adverse events	Light adverse events
Schweitzer et al. (2011)	Cigarette smoke-induced lung injury (LP)	• Pre-clinical • 20 mice • NR randomization of group division • Biochemical and immunohistochemical analysis • Inflammatory markers: caspase 3, via MAPK • Stem cell markers: anti-CD31b	• Mices	• Allogeneic MSCs derived from adipose tissue of animal and xerogenic (human) origin, expanded by culture • Administration IV • Single dose: 3×10^5 cells ASCs (in both experiments)	• Follow up of lung tissue: 1, 7, and 21 days after administration	The results suggest a useful therapeutic effect of adipose stem cells in both lungs and systemic injury induced by cigarette smoke and imply a pulmonary vascular protective function of paracrine factors derived from adipose stem cells.	NR (Not reported)	NR
Gao et al. (2013)	Acute Lung Injury (ALI)	• Pre-clinical • 25 Mices • RCT - control group (10) • Clinical, biochemical, immunohistochemical and wet-dry lung ratio analysis • Inflammatory marker: NO • Stem cell markers: PE-CD34, FITC—CD90 and PE-106 antibodies	• Mices	• Xerogenic MSCs derived from human adipose tissue, expanded by culture • Administration IV • Single dose MSC: $\sim 5 \times 10^5$ ASC	• Follow up: The culture medium was collected at 24 h, 48 h and 72 h; rat plasma was collected in 7 days.	ASCs were able to attenuate the severity of ALI and pulmonary edema.	NR (Not reported)	NR
Cho et al. (2014)	Asthma	• Pre-clinical • 20 mice • NR randomization of group division • Clinical, biochemical, immunohistochemical and histopathological analysis • Inflammatory markers: IL-4, IL-5, IL-10, IL-13, IFN-γ, TGF-β, Ig E, IgG1, and IgG2a, PGE2, IDO enzyme • Stem cell markers: (+): Sca1, CD44, CD90; (-): CD45, CD 117 and CD11b	• Mices	• Allogeneic MSCs derived from adipose tissue of animal origin, expanded by culture • Administration IV • 4 Doses: 1×10^7/mL ASC cells suspended in PBS (days 12, 13, 19 and 20)	• Follow up: airway hyperresponsiveness was assessed on day 23. The frequency of sneezing and nasal rubbing that occurred within 10 min of the last ovalbumin administration (day 23). The mice were euthanized on day 24. At least 48 h after the last OVA administration, serum was collected from the mice.	IV ASCs significantly reduced allergic symptoms and inhibited eosinophilic inflammation.	NR (Not reported)	NR
Feizpour et al. (2014)	COPD	• Pre-clinical • 36 guinea pigs • RCT- control group (6 via IT and 5 via IV) • Tracheal, biochemical and cytological responsiveness analysis • Inflammatory markers: IL-8 • Stem cell markers: feline anti-CD4 PE, anti-feline CD5 biotin and streptavidin APC	• Guinea pigs	• Allogeneic cryopreserved MSCs derived from adipose tissue of animal origin, expanded by culture • Administration IV and IT • Single dose: 0.3 mL PBS containing 10^6 ASCs (both lanes)	• Follow-up: 14 days	No significant changes were observed in the group that received ASCs IV.	NR (Not reported)	NR

(continued on next page)

Table 2 (Continued)

Authors	Pathology	Effectiveness analysis Study method	Participants	Intervention	Follow-up	Results observed	Safety analysis Serious adverse events	Light adverse events
Lee et al. (2014)	BLM-induced pulmonary fibrosis (PF)	• Pre-clinical • 40 mice • Did not describe the method of dividing the groups, whether it was randomized or not (control: $n = 10$) • Cytological, histological, immunohistochemical and TUNEL method analysis • Inflammatory markers: TGF-β • Stem cell markers: (+): CD73 and CD105; (-): CD14, CD34 and CD45	• Mices	• Culture-expanded xerogenic adipose tissue-derived MSCs • Administration IV • 4 Doses (1 every 2 weeks for 2 months) single: 3×10^5 ASCs	• Follow-up: mice were euthanized on day 16. Lungs were collected 2 weeks after the last dose of ASCs that occurred on day 14.	BLM-ASC treatment resulted in a significant decrease in the number of apoptotic and inflammatory cells, as well as a reduction in fibrosis score compared to group only with BLM.	NR (Not reported)	NR
Kim et al. (2014)	Elastase-induced pulmonary emphysema	• Pre-clinical • NR the number of Mices • NR randomization of group division • Image and molecular analysis (PCR) • Image analysis after 1, 4, 24, 72 and 168 h.	• Mices	• Xerogenic MSCs derived from human adipose tissue, expanded by culture • Administration IV • Single dose: 5×10^5 ASCs in 100 μL saline • Stem cell markers: NR	• Follow-up: Mices were euthanized after 1, 4, 24, 72 and 168 h.	The results show that injected MSCs were observed 1 and 4 h after injection and more MSCs remain in the emphysema lungs.	NR (Not reported)	NR
Trzil et al. (2014)	Asthma	• Pre-clinical • 9 cats • RCT- control group (4) • Clinical analysis, biochemistry, immunohistochemistry, cytology and imaging • Inflammatory markers: IL10, IgE, lymphocytes and eosinophils in BALF • Company-proven stem cells	• Cats	• Allogeneic cryopreserved MSCs derived from adipose tissue of animal origin, expanded by culture • Administration IV • 6 doses ($2 \times$ /month): 3.64×10^6 to 2.50×10^7 MSCs (average of 1.44×10^7 MSCs alive / infusion)	• Follow-up: Allergen challenges were performed weekly for 4 months after the first infusions. Subsequent challenges were performed bimonthly between months 4 and 8 and monthly from 8 months until the end of the study.	When given after the development of feline chronic allergic asthma, MSCs have failed to reduce airway inflammation. However, repeated administration of MSCs at baseline reduced airway remodeling at month 8 CT, although it was not maintained at month 12.	~1 month after study completion, one cat developed an aggressive sarcoma. post-death exam confirmed spindle cell sarcoma without evidence of other malignant or metastatic disease.	None
Dong et al. (2015)	Radiation-induced lung injury (LP)	• Pre-clinical • First part: 108 Mices • Second part: 48 mice • First part control: 12 (did not specify group division technique) • Control second part: 27 mice (did not specify group division technique) • Biochemical, immunohistochemical and histopathological analysis • Inflammatory markers: TGF-β1, TNF-α, PGE2, HGF, IL-10, COX1 enzyme, COX2 enzyme and IGF • Stem cell markers: CD11b, CD19, CD34, CD45, CD73, CD90, CD105 and HLA-DR....	• Mices	• Xerogenic MSCs derived from human adipose tissue, expanded by culture • Administration IV • Single dose: 5×10^6 ASCs (2 h after irradiation)	• Follow-up: Mices were euthanized on day 3, after 1 week, 2 weeks, 4 weeks, 12 weeks and 24 weeks to perform the necessary analyses.	The results confirmed that mesenchymal stem cells have the potential to limit pulmonary fibrosis after exposure to ionizing irradiation.	NR (Not reported)	NR

(continued on next page)

Table 2 (Continued)

Authors	Pathology	Effectiveness analysis Study method	Participants	Intervention	Follow-up	Results observed	Safety analysis Serious adverse events	Light adverse events
Fikry et al. (2015)	MTX-induced pulmonary fibrosis (PF)	• Pre-clinical (comparative) • 40 mice • RCT - control group (8) • Biochemical, immunohistochemical and histopathological analysis • Inflammatory and oxidative stress markers: IL4, TGF-β1, (MDA, GSH, SOD). • Stem cell markers (+): CD90 and CD105 and (-): CD34	• Mices	• Allogeneic MSCs derived from adipose tissue and culture-expanded rat bone marrow. • Administered intravenously • Low dosage: 2×10^6 cel. • High dosage: 4×10^6 cel	• Follow-up: mice were euthanized after 6 weeks	Both BM-MSCs and ASCs exerted antifibrotic effects on MTX as a model of pulmonary fibrosis, which can be attributed to their antioxidant and anti-apoptotic properties, therefore, they can be presented as promising candidates for the treatment of pulmonary fibrosis.	NR (Not reported)	NR
Perlee et al. (2019a)	Pneumosepsis caused by <i>Klebsiella pneumoniae</i>	• Pre-clinical • Mices (does not say total amount) • Has a control group, but does not specify group division methodology (4–8) • Biochemical, immunohistochemical and histopathological analysis • Inflammatory markers: Fibrin • Stem cell markers: CD32, CD45 mAb, CD90 mAb, CD16	• Mices	• MSCs derived from adipose tissue not reported origin, expanded by culture as well as cryopreserved • Administration IV • High single dose: 1×10^6 ASCs (1 or 6 h after infection) • Low single dose: 0.4×10^6 cells, 6 h after infection	• Follow-up: Analyzes were performed after euthanasia. Mices infused with ASCs 1 h after infection were sacrificed 4 h or 16 h after pneumonia induction; mice infused with ASCs 6 h after infection were sacrificed 48 h after pneumonia induction.	These data indicate that ASC-associated tissue factor is responsible for systemic activation of coagulation after ASC infusion, but not for the formation of microthrombi in the lungs or for the antibacterial effects.	NR (Not reported)	NR
Perlee et al. (2019b)	Pneumosepsis caused by <i>Klebsiella pneumoniae</i>	• Pre-clinical • 50 mice • RCT – control group (10) • Biochemical, immunohistochemical and histopathological analysis • Inflammatory markers: IL-1β, IL-6, TNF-α, MIP-2, MPO, E-selectin, VCAM-1 and MCP-1 • Stem cell markers: CD32, CD45 mAb, CD90 mAb, CD16	• Mices	• Allogeneic MSCs derived from adipose tissue not reported origin, expanded by culture • Administration IV • High single dose: 1×10^6 ASCs, 1 or 6 h after infection • Low single dose: 0.4×10^6 cel. 6 h after infection	• Follow-up: Mices were euthanized 16 or 48 h after pneumonia infusion	Both cultured and cryopreserved ASCs were able to reduce bacterial growth and dissemination during <i>K. pneumoniae</i> -induced pneumosepsis, with cryopreserved cells exerting a faster effect at the primary site of infection and with a dose-dependent effect.	NR (Not reported)	NR
Jiang et al. (2015)	Radiation-induced lung injury (LP)	• Pre-clinical • 90 Mices • RCT – control group (30) • Biochemical, immunohistochemical, localization (fluorescence microscopy) and histopathological analysis • Inflammatory markers: IL-1, IL-6, IL-10, TNF-α, TGF-β1 and HGF • Stem cell markers: CD11b-PE, CD29-PE, CD44-FITC and CD45-APC.	• Mices	• Allogeneic MSCs derived from rat adipose tissue, expanded by culture • Administration IV • Single dose: 5×10^6 ASCs (2 h after irradiation)	• Follow-up: days 1, 3, 7, 14 and 28	ASCs reduced serum levels of pro-inflammatory cytokines, increased levels of anti-inflammatory and regulated the expression of pro- and anti-apoptotic mediators to protect lung cells.	NR (Not reported)	NR

(continued on next page)

Table 2 (Continued)

Authors	Pathology	Effectiveness analysis Study method	Participants	Intervention	Follow-up	Results observed	Safety analysis Serious adverse events	Light adverse events
Mao et al. (2015)	Acute Lung Injury (ALI)	• Pre-clinical • NR number of Mices • NR randomization and division of groups • Clinical, biochemical, immunohistochemical and histopathological analysis • Inflammatory markers: KGF, Ang-1, IGF-1, PGE2, COX2 and 15-PGDH • Stem cell markers: (+): CD34, CD45; (-): CD90, CD105	• Mices	• Allogeneic MSCs derived from adipose tissue of animal origin, expanded by culture • Administration IV • High single dose: $\sim 5 \times 10^6$ ASCs • Low single dose: $\sim 5 \times 10^5$ ASCs	• Follow-up: 24 h after P. aeruginosa infection	ASCs exhibited protective effects against pulmonary P. aeruginosa infection.	NR (Not reported)	NR
Tashiro et al. (2015)	BLM-induced pulmonary fibrosis (PF)	• Pre-clinical • Mices (did not say quantity) • Has control (did not specify group division technique) • Biochemical, immunohistochemical and histopathological analysis • Inflammatory markers: TGF-β, integrin-αv, TNF-α, VEGF, Nrf2, MMP-2, ROS, and IGF • Stem cell markers: CD90, CD205, CD29, Sca1, CD79α, CD45, CD14 and CD11	• Mices	• Allogeneic MSCs derived from the adipose tissue of young mices, expanded by culture • Administration IV • Single dose: 5×10^5 ASCs	• Follow-up: all mices were euthanized on day 21 for analysis.	The fibrosis score in the lungs of mices that received BLM was decreased in those treated with yASCs, however, the score in those treated with oASCs remained high.	NR (Not reported)	NR
Reddy et al. (2016)	BLM-induced pulmonary fibrosis (PF)	• Pre-clinical (comparative) • 50 mices • RCT - control group (10) • Radiological, biochemical, immunohistochemical and histopathological analysis • Inflammatory markers: IL2, IL1b, TNF-α, TGF β, bFGF, CTGF, Col3a1, Col1a1, MMP-TIMP • Stem cell markers: CD34, CD45, CD73, CD90, CD105, CD166	• Mices	• Xerogenic MSCs derived from human adipose tissue, subjected to enzymatic degradation • IV administration, 3 doses (3 days between) • Dose: 40×10^6 cel./kg (equivalent in a human to 2×10^6/kg)	• Follow-up: all mices were euthanized on day 24 for analysis.	Survival was significantly prolonged and better in mices treated with ASC than pirfenidone. After the infusions, the disease characteristics disappeared significantly on day 21, it also demonstrated homing and graft potential towards the damaged lung tissue, being detected on day 24 after administration.	NR (Not reported)	NR
Pedrazza et al. (2017)	Acute Lung Injury (ALI)	• Pre-clinical • NR total number of mices • NR randomization or division of groups • Cytological, histological, immunohistochemical and biochemical analysis • Inflammatory markers: IL-6, TNF-α, IL-10, COX-2, GAPDH enzyme, NF-κB • Stem cell markers: (+): CD73 and CD105; (-): CD14, CD34 and CD45	• Mices	• Allogeneic MSCs derived from adipose tissue of animal origin, expanded by culture • Retro orbital IV administration • Single dose: 5×10^5/100 μL PBS	• Follow-up: After 7 days, animals that were still alive were anesthetized. Analyzes were performed 12 h after administration of ASCs.	The mices that received MSCs had a significantly higher survival rate compared to the LPS group, improvements in cytological, histological and biochemical analyses, indicating a possible action of MSCs via neutrophils.	NR (Not reported)	NR

(continued on next page)

Table 2 (Continued)

Authors	Pathology	Effectiveness analysis Study method	Participants	Intervention	Follow-up	Results observed	Safety analysis Serious adverse events	Light adverse events
Chen et al. (2018)	Silicosis-induced pulmonary fibrosis (PF)	• Pre-clinical • 20 mice • RCT - control group (5) • Biochemical, immunohistochemical and histopathological analysis • Inflammatory markers: TNF-α, IL-1β, IL-6 and IL-10 • Stem cell markers: CD44, CD45, CD90, CD73 and CD11b	• Mices	• Allogeneic MSCs derived from rat adipose tissue, expanded by culture • Administration IV • Single dose: 5×10^5 ASCs (24 h after exposure to silica)	• Follow-up: 28 days	Treatment with transplant ASCs led to a remissive effect on pulmonary fibrosis.	NR (Not reported)	NR
Felix et al. (2020)	BLM-induced pulmonary fibrosis (PF)	• Pre-clinical • 40 mice • RCT - control group (10) • Clinical, biochemical, immunohistochemical and histopathological analysis • Inflammatory and fibrotic markers: fibrinogen, Von Willebrand factor, PDGF, NOS, IL-17, TGF-β, VEGF, endothelin-1 and the immunogenic Col. V in lung tissue of mice with MBL lesion after treatment with MSCs • Stem cell markers: CD34, CD45, CD90	• Mices	• Allogeneic MSCs derived from adipose tissue of animal origin, expanded by culture and ASC-MC. • Administration IV • Single dose high MSC: 1×10^6 ASCs in 0.2 mL of serum free medium (10 days after induction) • DU MC: 200 μL, derived from 1×10^6 cel. (10 days after induction)	• Follow-up: 14 and 21 days	Mices that were injected with MSCs and MC showed improvement in general status, in addition to presenting an early anti-inflammatory action and improvement in fibrotic markers.	NR (Not reported)	NR
Radwan et al. (2020)	Amiodarone-induced pulmonary fibrosis (PF)	• Pre-clinical • 40 mice • RCT - control group (10) • Biochemical, immunohistochemical and histopathological analysis • Inflammatory markers: CC16 protein, CK19 protein, αSMA. • Stem cell markers (+): CD90 and CD105; and (-): CD34	• Mices	• Allogeneic MSCs derived from culture-expanded rat adipose tissue • Administered intravenously • Low dosage: 2×10^6 cel. • High dosage: 4×10^6 cel.	• Follow-up: At the end of 12 weeks in order to confirm induction of pulmonary fibrosis, three animals were randomly euthanized from the control and amiodarone-treated groups. After the end of the experimental period (2 months), all animals fasted for 12 h and blood samples were collected	Treatment with ASC resulted in improvement of biochemical and histopathological parameters.	NR (Not reported)	NR

PF, Pulmonary Fibrosis; BLM, Bleomycin; MTX, Methotrexate; ALL, Acute Lung Injury; LP, Lung Injury; COPD, Chronic Obstructive Pulmonary Disease; RCT, Randomized Trial with a Control group; α SMA, α Smooth Muscle Actin; IL, Interleukin; TGF- β , Transforming Growth Factor Beta; TNF- α , Tumor Necrosis Factors Alpha; bFGF, Basic Fibroblast Growth Factor; CTGF, Connective Tissue Growth Factor; Col., Collagen; MMP, Metalloproteinases; VEGF, Endothelial Growth Factor; Nrf2, Factor 2 Related to Nuclear erythroid Factor 2; ROS, Reactive Oxygen Species; IGF, Insulin-Like Growth Factor; MDA, Malondialdehyde, GSH, Reduced Glutathione; SOD, Superoxide Dismutase; HGF, Hepatocyte Growth Factor; PG, Prostaglandin; MIP, Macrophage Inflammatory Protein, MPO, Myeloperoxidase; VCAM, Vascular Cell Adhesion Molecule; MCP, Monocyte Chemotactic Protein; PDGF, Platelet-Derived Growth Factor; NOS, Nitric Oxide Synthase; NO, Nitric Oxide; KGF, Keratinocyte Growth Factor; Ang-1, Angiotensin 1; PGDH, Hydroxyprostaglandin Dehydrogenase; IFN- γ , Interferon-Gamma; Ig, Immunoglobulin; IDO, Indoleamine 2,3 Dioxygenase; BALF, Bronchoalveolar Lavage; IV, Intravenous; IT, Intratracheal; GAPDH, Glyceraldehyde-3-Phosphate Dehydrogenase; MSC, Mesenchymal Stem Cells; ASC-MC, Conditioned Medium from in vitro Adipose Cell Culture; DU, Single Dose; cel., Cells; mL, Milliliter; μ L, Microliter; CD, Differentiation Cluster; ASCs, Adipose issue-derived Stem Cells; kg, Kilogram; PE, Phycoerythrin; FITC, Fluorescein Isothiocyanate; APC, Antigen Presenting Cell; HLA, Human Leukocyte Antigen System; mAb, Monoclonal Antibodies; NR, Does Not Refer; yASCs, ASCs taken from young animals; oASCs, ASCs taken from elderly animals; BM-MSCs, Bone Marrow-derived Stem Cells; LPS, Lipopolysaccharide; NETs, Extracellular Neutrophil Traps; NR, Does Not Refer.

Table 3
Published clinical trials on the administration of ASCs in chronic or acute lung diseases.

Authors	Pathology	Effectiveness analysis Study method	Participants	Intervention	Follow-up	Results observed	Safety analysis Serious adverse events	Light adverse events
Zheng et al. (2014)	ARDS	• Single-center, randomized, double-blind, placebo-controlled trial. • 12 Patients • RCT - control • Primary endpoint: occurrence of adverse events. Secondary endpoints included the following: PaO₂/FiO₂ ratio, length of stay, days without ventilation, days without ICU on day 28, IL-6 and IL-8.	• 12 Patients with ARDS aged at least 18 years and diagnosed within 48 h with a PaO₂/FiO₂ ratio of < 200. • Average age in the MSCS group: 66.7 years in control: 69.8 years	• Follow-up: days 1, 3, 5, 7, 14 and 28 (or until hospital discharge or death, whichever comes first).	• Adipose tissue-derived allogeneic MSCs expanded by culture in patient serum • Administered IV • DU: 1×10^6 /kg. • CD73, CD90, CD105, CD34, CD45 and HLA-DR....	There were no infusion toxicity or serious adverse events related to MSC administration and there were no significant differences in the overall number of adverse events between the two groups.	None	One patient in each group had diarrhea one day after treatment resolved within 48 h. One patient in the MSC group developed a rash in the chest area after the infusion and resolved spontaneously over 24 h
Leng et al. (2020)	SARS-COV-2	• Concept proof • 7 Patients • RCT • 1st safety endpoint: secondary infection and life-threatening adverse events. 1st efficacy endpoint: level of variation in cytokines, serum C-reactive protein and oxygen saturation. 2nd efficacy endpoint: total lymphocyte and subpopulation count, chest CT, respiratory rate, patient symptoms, therapeutic measures and their results.	• 7 patients with COVID (CRP +) and unresponsive to conventional therapies with persistent worsening of the condition • Ages ranging between: 45 and 75 years old	• Average follow-up: 14 days	• MSCs of undefined origin • Administered intravenously • Single dose: 1×10^6 /kg. • Does not describe stem cell (CD) markers	No acute infusion-related or allergic reactions were observed within two hours of transplantation. Likewise, no delayed hypersensitivity or secondary infections were detected after treatment.	None	None
Sánchez-Guijo et al. (2020)	COVID-19	• Concept proof • 13 Patients with COVID-19 (CRP + CX or chest CT) on mechanical ventilation • No control group • Clinical and radiological analysis • Laboratory analysis of inflammatory markers: C-reactive protein, LDH, D-dimer and ferritin	• 3 Patients with COVID-19 (CRP + Rx or CT) and on mechanical ventilation • Average age: 60 years old • Average time between MSC dose and extubation: 7 days	• Average follow-up: 14 days	• Culture-expanded adipose-derived allogeneic MSCs • Administered IV • Average number of cells per dose: 0.98 (IQR 0.5) $\times 10^6$ /kg. • 1 pct: 3 doses; 2pcts: 2 two; 10 pcts: 2 doses • + CD90 and CD105; - CD34	Treatment with ASC proved to be safe and resulted in a decrease in inflammatory parameters, as well as an increase in lymphocytes, especially in those patients with clinical improvement.	None	None

COVID-19, 2019 Coronavirus Disease; ARDS, Acute Respiratory Distress Syndrome; PCR, Reverse Transcription followed by Polymerase Chain Reaction; X-Ray, Radiography; CT, Computed Tomography; RCT, Randomized Trial; LDH, Lactate Dehydrogenase; FiO₂, Inspired Oxygen Fraction; PaO₂, Arterial Oxygen Pressure; ICU, Intensive Care Units; IL, Interleukin; MSC, Mesenchymal Stem Cells; IV, Intravenously; kg., Kilogram; pct (s), Patient(s); CD, Differentiation Cluster; HLA, Human Leukocyte Antigen system; DU, Single Dose; IQR, Interquartile Range; ASCs, Adipose tissue-derived Stem Cell; sCABP, Severe Community-Acquired Bacterial Pneumonia; IMV, Invasive Mechanical Ventilation.

Table 4
Unpublished clinical trials on the administration of ASCs in chronic or acute lung diseases.

Title (year)	Study method	Population	Intervention	Comparator	Outcomes	Status
Safety and Efficacy of Adipose Derived Stem Cells for Chronic Obstructive Pulmonary Disease (2014)	• Phase I/II Open-label, single group assignment, Non-Randomized, Multi-center Study	• 26 patients (Age 18 to 85, prior diagnosis of moderate to severe COPD; GOLD IIa, III, IV; Cognitive competitiveness; life expectancy > 6 months, written informed consent)	• 100–240cc of lipoaspirate will be extracted from the patient. The SVF will be isolated with minimal manipulation. The cell pellet will be reconstituted in saline solution and administered intravenously to the patient as a single dose of autologous adipose derived stem cells. The dosage was not described	None	• Primary outcomes: FEV1 Decline [Time Frame: 12 months] and Number of Adverse Events [Time Frame: 12 months] • Secondary outcomes: Secondary Efficacy Objective [Time Frame: 12 Months]	Completed
Safety, Tolerability and Preliminary Efficacy of Adipose Derive Stem Cells for Patients With COPD (2014)	• Phase I Open-Label, single group assignment, study to assess safety and tolerability	• 9 patients (males and females ≥18 years. Cognitive competitiveness. Diagnosis of at least moderate, COPD, Diffusing capacity impairment, assessed by single breath test, life expectancy > 12 months, written informed consent, non-smoker or past smoker, with 20 pack-years or more history)	• 100–240cc of lipoaspirate will be extracted from the patient. The SVF will be isolated with minimal manipulation. The cell pellet will be reconstituted in saline solution and administered intravenously to the patient as a single dose of autologous adipose derived stem cells. The dosage was not described	None	• Primary outcomes: Safety of adipose derived stem cells (ADSC) in Patient with COPD [Time Frame: 12 months] • Secondary outcomes: Efficacy of ADSC in improving Shortness of Breath (SOB) [Time Frame: 2, 6 and 12 months]; Efficacy of ADSC In Pulmonary Function Test (PFTs) [Time Frame: 2, 6, 12 months]; Efficacy of adipose derived stem cell in 6 MWT [Time Frame: 2, 6, 12 months]; Efficacy of adipose derived stem cells in patient's perceived exertion [Time Frame: 2, 6, 12 months]; Efficacy in Quality of life using George's Respiratory Questionnaire [Time Frame: 2, 6, 12 months]; Efficacy in Quality of life using the Chronic Respiratory questionnaires [Time Frame: 2, 6, 12 months].	Terminated
Adipose Derived Stem Cells Transplantation for Chronic Obstructive Pulmonary Disease (2016)	• Phase I/II open-label single-dose study in subjects with significant COPD.	• 20 patients (Age 40 to 80 + prior diagnosis of moderate to severe COPD GOLD IIa, III, IV)	• Autologous SVF and PRP will be transfused into 20 COPD patients.	None	• Primary outcomes: SGOT [Time Frame: 1 month], SGPT [Time Frame: 1 month] • Secondary outcomes: Respiration rate [Time Frame: 1 month, 6 months, 12 months], 6 min walk test [Time Frame: 1 month, 6 months, 12 months], rates of panic attacks [Time Frame: 1 month, 6 months, 12 months], CRP concentration [Time Frame: 6 months, 12 months].	Unknown
Adipose Derived Cells for Chronic Obstructive Pulmonary Disease (2014)	• Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects	• 0 patients	• Adipose Derived Stem Cells. The dosage or origin was not described	None	• Primary outcomes: assess safety • Secondary outcomes: efficiency in improving the disease pathology of patients with diagnosed with chronic obstructive pulmonary disease	Withdrawn
Safety and Efficacy of Adipose Derived Stem Cells for Chronic Obstructive Pulmonary Disease (2012)	• Phase I/II Open-label, Non-Randomized, Multi-Center Study	• 0 patients	• SVF harvested from Autologous Adipose Tissue will be deliver after processing via IV and Inhalation	None	• Primary outcomes: Functional Capacity improved compared to baseline [Time Frame: 3 months, 6 months], Number of adverse events [Time Frame: 3 months, 6 months] • Secondary outcomes: Quality of Life improved compared to baseline [Time Frame: 3 months, 6 months].	Withdrawn (company dissolved)
Cell Therapy in Advanced Chronic Obstructive Pulmonary Disease Patients (2015)	• Phase I/II randomized, open-label, placebo-control study	• 20 patients (COPD patients with persistent dyspnea in stage 2 or 3 of the dyspnea scale score; Eligibility for pulmonary rehabilitation program; No smoking or smoking cessation for at least 6 months, absence of emphysema)	• BMMC: 1×10^8 B.M. in 30 mL saline IV. • ASC: 1×10^8 ASC in 30 mL saline IV. • BMMC + ASC: 5×10^7 ASC + 5×10^7 B.M. in 30 mL saline IV.	No interventions will be performed other than conventional (in-course) treatment.	• Primary outcomes: Pulmonary morphology [Time Frame: 9 months after procedure] • Secondary outcomes: Pulmonary morphology [Time Frame: 9 months after procedure]; Pulmonary function [Time Frame: 12 months after procedure]	Unknown
Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells In Chronic Lung Disorders (AdSVF-COPD) (2016)	• Phase I/II non-randomized, single-blind, study	• 100 patients (18–80 years, prior diagnosis of moderate to severe COPD; GOLD IIa, III, IV; no positive hepatitis)	• Experimental: Isolation and IV administration of cellular stem/stromal cells from subdermal adipose-derived cellular stromal vascular fraction. Intervention: Procedure: SVF • Experimental: Normal Saline IV Arm 3 with SVF cells	None	• Primary outcomes: Safety – Pulmonary Function [Time Frame: 12 months Evaluate Function and Adverse Events], Change from Baseline Respiratory Rate [Time Frame: 1 month, 6 month, 1 year]. • Secondary outcomes: GOLD Classification [Time Frame: 1 year]; Change from baseline 6 Min Walk Test [Time Frame: 12 Months]; Exercise capacity measured by distance a patient can walk in 6 min timeframe; Change from Baseline Lung X-Ray [Time Frame: 6 months, 12 months]; Change from Baseline SGOT Blood Testing [Time Frame: 1 Month]; Change from Baseline SGPT Blood Testing [Time Frame: 1 Month]; Pulmonary Function Testing [Time Frame: Baseline, 6 Months].	Enrolling by invitation
Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19 (2020)	• Phase II randomized, double-blind, placebo-control study conducted in multiple clinic facilities	• 200 participants (> 18 years; male or female; have banked AdMSCs in Celltex; written informed consent; highly susceptible to SARS-CoV-2 infections, no terminal stages; no previous COVID-19 history, SARS-CoV-2 RT-PCR or equivalent tests negative; SARS-CoV-2 IgM and IgG negative)	• Three doses of 200 million autologous adipose derived mesenchymal stem cells via intravenously infusion every three days	• Three doses of placebo via intravenously infusion every three days.	• Primary outcomes: Assessment of the total number of AEs/SAEs related and non-related with the medication [Time Frame: 6 months]; Proportion of AEs/SAEs related and non-related with the ASCs infusions as compared to the control group [Time Frame: 6 months]; COVID-19 incidence rates [Time Frame: 6 months] • Secondary outcomes: Proportion of SARS-CoV-2 infected subjects testing [Time Frame: 6 months]; Proportion of mild, classic, severe and critically severe symptomatic SARS-CoV-2 infected subjects [Time Frame: 6 months]; Change of proportion of SARS-CoV-2 infected subjects IgM/IgG + against SARS-CoV-2. [Time Frame: 6 months]; Change of lymph count from the baseline [Time Frame: 6 months]; Change of PaO2 from the baseline [Time Frame: 6 months]; Compare the proportion of severe COVID-19 pneumonia cases development [Time Frame: 6 months]; COVID-19 mortality rates [Time Frame: 6 months]; Change of CRP (mg/L), D-dimer (mg/L), Procalcitonin (ug/L), pro-BNP (pg/mL), B1 (mg/dL), Cr (mg/dL), from the baseline [Time Frame: 6 months]; Change in cytokine panels (IL-1 β , IL-6, IL-8, IL-10, TNF α) from the baseline [Time Frame: 6 months]; Proportion of SARS-CoV-2 RT-PCR positive to negativity [Time Frame: 6 months]; Quantifying viral RNA in stool for baseline and final follow-up. [Time Frame: 6 months].	Not yet recruiting

(continued on next page)

Table 4 (Continued)

Title (year)	Study method	Population	Intervention	Comparator	Outcomes	Status
Clinical Study for Subjects With COVID-19 Using Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells (ADMSCs) (2021)	•Phase II, randomized, double blind and placebo controlled study conducted initially in a single clinic facility.	•30 participants (> 18 years; male or female; Diagnosed as COVID-19 based upon SARS-CoV-2 RT-PCR + test; Clinical diagnosis meets severe and/or critical parameters; Male participants must be willing to ensure their partners do not become pregnant either by practicing abstinence or the use of condoms during sexual activity)	•Three separate doses of 200 million allogeneic adipose-derived mesenchymal stem cells via intravenously infusion on days 0, 3, and 6 with a total of 600 million ADMSCs during 7 days in addition to their standard of care.	•The control group will receive placebo infusion on day 0, 3 and 6 along with standard of care.	•Primary outcomes: Frequency and nature of adverse events occurring during the study based on the rate of all ASC-associated AEs in all subjects. [Time Frame: 6 months]; Safety for ASCs based upon incidence of all AEs [Time Frame: 6 months]; Comparison the mortality rate between treating group v.s. control group [Time Frame: 6 months] •Secondary outcomes: Change of SOFA score as compare to the baseline [Time Frame: 6 months]; Organ functional tests including blood specific enzymes and proteins [Time Frame: 6 months]; Days of weaning from mechanical ventilation [Time Frame: 6 months]; Duration (days) of ICU monitoring [Time Frame: 6 months]; Days of hospitalization [Time Frame: 6 months]; Proportions of SARS-CoV-2 RT-PCR change to negative from respiratory tract specimens using CDC standard method [Time Frame: 6 months]; Proportions of quantifying viral RNA in stool change to negative in final follow-up using CDC standard method [Time Frame: 6 months]; Proportions of blood SARS-CoV-2 antibodies IgM/IgG show positive [Time Frame: 6 months].	Not yet recruiting
Clinical Study of Adipose Derived Mesenchymal Stem Cells for Treatment of Pulmonary Arterial Hypertension (2019)	•Phase I/II, randomized, double masked, parallelly assignement study	•60 participants (40–75 years; male or female; COPD with moderate to severe pulmonary hypertension; lifetime > 6 months; signed the informed consent in person)	•The MSCs of $1 \times 10^6/\text{kg}$ will be given in Central venous catheterization for injection at a total 100 mL. The injection cycle was once every week of two times.	•Conventional drug therapy (expectorant, bronchodilator)	•Primary outcomes: Change in Pulmonary Vascular Resistance from Baseline [Time Frame: Baseline, 4, 12 and 24 weeks] •Secondary outcomes: Change from Baseline in Participant Quality of Life Using the ASCs [Time Frame: Baseline, 4, 12 and 24 weeks]; Change in Plasma NT-pro-BNP levels [Time Frame: Baseline, 4, 12 and 24 weeks]; Change in the IL- 3β , IL-6, PGE-2, TGF- β , TNF- α and IGF-1 (ng/dL) [Time Frame: Baseline, 4, 12 and 24 weeks]; Incidence of Treatment Adverse [Time Frame: Baseline, 4, 12 and 24 weeks]; Change in Six Minute Walk distance [Time Frame: Baseline, 4, 12 and 24 weeks]	Unknown
Evaluate Safety and Efficacy of Intravenous Autologous ADMSCs for Treatment of Idiopathic Pulmonary Fibrosis (2014)	•Phase I/II, Prospective, Multicentric, Open Label, Randomized, Interventional Study	•60 participants (40–75 years; male or female; COPD with moderate to severe pulmonary hypertension; lifetime > 6 months; signed the informed consent in person)	•Single dose of SVF IV; •3 IV doses of 2 million/kg ASCs each, given at weekly intervals.	•CCO ≤ 10 mg/day or ≤ 20 mg alternating days + Immunosuppressants 2 mg/kg/day, not exceeding 150 mg/day + Anticoagulants up to 1800 mg/day + Pirfenidone up to 1200 to 1800 mg/day.	•Primary outcomes: Incidence of treatment emergent AEs in the study [Time Frame: 9 Month]. •Secondary outcomes: Change in predicted FVC% at EOS [Time Frame: 9 Month]; Change in predicted DLCO% at EOS [Time Frame: 9 Month]; Change in the 6MWT at EOS [Time Frame: 9 Month]; Changes in the disease extent and severity as reflected by HRCT (64 SLICE) at EOS from randomization [Time Frame: 9 Month].	Unknown
Study of Intravenous Administration of Allogeneic Adipose Stem Cells for COVID-19 (CoronaStem1) (2020)	•Phase I, open label, single group comparison with cohort of contemporaneous non-treated patients.	•10 participants (Admitted to hospital as inpatient; respiratory distress; bilateral lung infiltrates; supplemental oxygen started but NOT intubated or ventilated; COVID-19 positive antigen test; time from enrollment to treatment < 24 h; age: 18–80 years; gender: any; suitability for cellular therapy; preserved cognitive function)	•Adipose stem cells derived from screened donor lipos aspirate and culture expanded. The dosage was not described.	None	•Primary outcomes: Frequency of all AEs [Time Frame: Through study completion, an average of three months]; Frequency of infusion related SAEs [Time Frame: 6 h post infusion]; Frequency of SAEs [Time Frame: Through study completion, an average of three months]; •Secondary outcomes: Mortality [Time Frame: Study days 0–28]; Ventilator Free Days [Time Frame: Study days 0–28]; ICU Free Days [Time Frame: Days 0 through 28]; Total Hospital Days [Time Frame: Days 0 through discharge, an average of 28 days]; Total ICU Days [Time Frame: Days 0 through discharge, an average of 28 days]; Improvement in Oxygenation [Time Frame: Study days 0, 2, 4, 6]	Completed
Adipose-derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome (2013)	•Phase I, randomized, triple blinded, parallelly assignement study.	•20 participants (ARDS diagnosed using Berlin definition; at least 18 years of age; acute onset of ARDS; Bilateral opacities in chest radiography; No cardiac failure; Pao2/FiO2 ratio < 200)	•One dose of 1×10^6 allogeneic adipose-derived mesenchymal stem cells/kg body weight intravenously within 48 h of enrollment.	•One dose of Intravenous saline infusion	•Primary outcomes: Compare the adverse events between mesenchymal stem cell treatment and placebo groups [Time Frame: From day 0 at the start of treatment to day 28]. •Secondary outcomes: Hospital indices by treatment group [Time Frame: From admission to discharge] •Primary outcomes: Change in 6MWD at Day 60 [Time Frame: Baseline to Day 60]; •Secondary outcomes: Change in 6MWD at Day 30 [Time Frame: Baseline to Day 30]; Change in Pulmonary Function Tests (PFTs) [Time Frame: Baseline to Day 30 and Day 60]; Change in oxygenation [Time Frame: Baseline to Day 30 and Day 60]; Change in biomarker levels [Time Frame: Baseline through Day 30]	Unknown
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 ‘Long Haul’ Pulmonary Compromise (2021)	•Phase IIa, randomized, open-label, parallelly assignement study.	•0 participants	•IV ASCs (~18.5 million cells) on Day 0, Day 2, and Day 4. •IV ASCs (~37 million cells) on Day 0, Day 2, and Day 4.	None	Withdrawn (Replaced by a different protocol.)	

(continued on next page)

Table 4 (Continued)

Title (year)	Study method	Population	Intervention	Comparator	Outcomes	Status
A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-aMSCs) to Provide Protection Against COVID-19 (2020)	• Phase II, Open Label, Single-Center, Clinical Trial	• 56 participants (Men, and women > 65 years OR works in high-risk environment OR has underlying conditions; have previously banked their cells at Hope Biosciences; no signs or symptoms of infection, subject provides written informed consent, agrees to the collection of venous blood per protocol.)	• Five IV infusions of autologous, adipose-derived mesenchymal stem cells.	None	• Primary outcomes: Incidence of hospitalization for COVID-19 [Time Frame: Week 0 through week 26]; Incidence of symptoms for COVID-19 [Time Frame: week 0 through week 26] • Secondary outcomes: Absence of upper/lower respiratory infection [Time Frame: Weeks 0 through 26]; Glucose, Ca, Albumin, Total protein, Na, total carbon dioxide, Cl, AP, total BUN, ALT, AST, Cr, IL-1, MCP-1b, GHB, MCV, Platelets, CRP [Time Frame: Weeks 0, 6, 14, 26]; White blood cells [Time Frame: Weeks 0, 6, 14, 26]; Red blood cells [Time Frame: Weeks 0, 6, 14, 26]; Hemoglobin [Time Frame: Weeks 0, 6, 14, 26]; Hematocrit [Time Frame: Weeks 0, 6, 14, 26]; Neutro [Time Frame: Weeks 0, 6, 14, 26]; Lymphs, Eos, Mono, Baso, [Time Frame: Weeks 0, 6, 14, 26]; Absolute neutro, Absolute lymphs, Absolute mono, Absolute eos, Absolute baso [Time Frame: Weeks 0, 6, 14, 26]; Absolute immature granulocytes [Time Frame: Weeks 0, 6, 14, 26]; INR [Time Frame: Weeks 0, 6, 14, 26]; Prothrombin time [Time Frame: Weeks 0, 6, 14, 26]; IL-6 and IL-10 [Time Frame: Weeks 0, 6, 14, 26]; SP-36 [Time Frame: Weeks 0, 6, 14, 26]; PHQ-9 [Time Frame: Weeks 0, 6, 14, 26] • Primary outcomes: All-cause mortality rate at Day 28 [Time Frame: Baseline to Day 28] • Secondary outcomes: All-cause mortality rate at Days 60 and 90; Number of ventilator-free days through Day 28; Number of ICU days through Day 28; Clinical status at Day 28; Change in oxygenation [Time Frame: Baseline to Day 2, Day 4, Day 6, Day 14, Day 28]. • Primary outcomes: Change in 6MWD at Day 60 [Time Frame: Baseline to Day 60] • Secondary outcomes: Change in 6MWD at Day 30 [Time Frame: Baseline to Day 30]; Relief of symptoms on Day 30 and Day 60 [Time Frame: Baseline to Day 30 and Day 60]; Change in Pulmonary Function [Time Frame: Baseline to Day 30 and Day 60]; Change in oxygenation [Time Frame: Baseline to Day 30 and Day 60]; Change in biomarker levels [Time Frame: Baseline to Day 60]	Completed
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome (2021)	• Phase IIa Randomized, Placebo-Controlled Study	• 0 participants	• ASCs IV (two vials or a total of ≈30 million cells) on Day 0, Day 2, and Day 4	• Placebo IV (two vials) on Day 0, Day 2, and Day 4	• Primary outcomes: All-cause mortality rate at Day 28 [Time Frame: Baseline to Day 28] • Secondary outcomes: All-cause mortality rate at Days 60 and 90; Number of ventilator-free days through Day 28; Change in oxygenation [Time Frame: Baseline to Day 2, Day 4, Day 6, Day 14, Day 28]. • Primary outcomes: Change in 6MWD at Day 60 [Time Frame: Baseline to Day 60] • Secondary outcomes: Change in 6MWD at Day 30 [Time Frame: Baseline to Day 30]; Relief of symptoms on Day 30 and Day 60 [Time Frame: Baseline to Day 30 and Day 60]; Change in Pulmonary Function [Time Frame: Baseline to Day 30 and Day 60]; Change in oxygenation [Time Frame: Baseline to Day 30 and Day 60]; Change in biomarker levels [Time Frame: Baseline to Day 60]	Withdrawn (Replaced by a different protocol.)
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise (BR) (2021)	• Phase IIa Randomized, Placebo-Controlled study	• 60 participants (prior laboratory-confirmed SARS-CoV-2 infection; < 1 week negative SARS-CoV-2 test; at least moderate or severe post-COVID-19 pulmonary symptoms for at least 3 months which have resulted in reduced physical functioning compared to pre-COVID-19 status; willing to follow contraception guidelines).	• 2, 4 or 6 MSC vials IV (approximately 15million cells/vial) on Day 0, Day 2, or Day 4 depending on assignment to treatment group: Group A: 2 MSC vials infused on D0 and 2 vials of placebo on D2 and D4; Group B: 2 MSC vials infused on D0 and D2 and 2 vials of placebo on D4; Group C: 2 MSC vials infused on D0 and D4 and 2 vials of placebo on D2; Group D: 2 MSC vials infused on D0, D2 and D4	• 6 vials of placebo will be intravenously infused on Day 0, Day 2, or Day 4.	• Primary outcomes: All-cause mortality rate at Day 28 [Time Frame: Baseline to Day 28] • Secondary outcomes: All-cause mortality rate at Days 60 and 90; Number of ventilator-free days through Day 28; Change in oxygenation [Time Frame: Baseline to Day 2, Day 4, Day 6, Day 14, Day 28]. • Primary outcomes: Change in 6MWD at Day 60 [Time Frame: Baseline to Day 60] • Secondary outcomes: Change in 6MWD at Day 30 [Time Frame: Baseline to Day 30]; Relief of symptoms on Day 30 and Day 60 [Time Frame: Baseline to Day 30 and Day 60]; Change in Pulmonary Function [Time Frame: Baseline to Day 30 and Day 60]; Change in oxygenation [Time Frame: Baseline to Day 30 and Day 60]; Change in biomarker levels [Time Frame: Baseline to Day 60]	Not yet recruiting
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory Distress (2021)	• Phase II, Randomized, parallelly assigned, quadruple blinded study	• 60 participants (prior laboratory-confirmed SARS-CoV-2 infection; < 1 week negative SARS-CoV-2 test; hospitalized with at least "severe" COVID-19-induced ARD or ARDS; requires oxygen supplementation at Screening; willing to follow contraception guidelines).	• ASCs IV (two vials or a total of ≈ 30 million cells) on Day 0, Day 2, and Day 4	• Placebo IV (two vials) on Day 0, Day 2, and Day 4	• Primary outcomes: All-cause mortality rate at Day 28; Incidence of all adverse events (AEs) [Time Frame: Baseline through study completion at Day 90]; Incidence of treatment-emergent adverse events [Time Frame: Baseline through study completion at Day 90]; Incidence of severe adverse events [Time Frame: Baseline through study completion at Day 90]; Incidence of infusion-related adverse events [Time Frame: Baseline to Hour 4] • Secondary outcomes: All-cause mortality rate at Day 60 and 90; Number of ventilator-free days through Day 28; Number of ICU days through Day 28; Change in clinical status [Time Frame: Baseline to Day 28]; Change in clinical status as assessed using the WHO Clinical Progression Scale (0–10 scale, where lower score means a better outcome) at Day 28; Change in oxygenation [Time Frame: Baseline to Day 14 Day 28, and Day 60]. • Primary outcomes: Number of AEs [Time Frame: One year];	Recruiting
Clinical Study to Assess the Safety and Preliminary Efficacy of HCR040 in Acute Respiratory Distress Syndrome (2020)	• Phase I (open label) study and Phase II, randomized, controlled, double-blinded study	• PI: 6 participants with moderate to severe ARDS will be included in 2 sequential cohorts. • PI: 20 participants with moderate to severe ARDS will be randomly divided into two groups (control and treated).	• PI: Open label IV dose escalation, 3 patients in cohort 1 (1 million cells/kg) and 3 patients in cohort 2 (2 million cells/kg) • PI: Maximum tolerated dose IV (1 million cells/kg or 2 million cells/kg).	• PI: None • PI: IV vehicle solution.	• Primary outcomes: Average stay in the ICU 28 days after the administration of HCR040; SOFA index at 3, 7, 14, 21, and 28 days after the administration of HCR040; Mechanical ventilation-free days 28 days after the administration of HCR040; Daily pulmonary mechanics values (Ppl, DP, CRS) [Time Frame: One year]; Determination of lung damage using the Murray scale at day 3, 7, 14 and 28 after the administration of HCR040; Vaso-pressor-free days 28 days after the administration of HCR040; ICU-free days 28 days after the administration of HCR040 • Secondary outcomes: Mortality at Day 28; Mortality at Days 60 and 90; Number of ventilator-free days [Time Frame: Randomization through Day 28]; Improvement in oxygenation [Time Frame: Randomization to Day 2, Day 4, Day 6, Day 14, Day 28]; SOFA score at Day 28.	Recruiting
Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells for COVID-19-Induced Acute Respiratory Distress (2021)	• Phase II, Randomized, parallelly assigned, double blinded study	• 0 participants	• 1 × 10 ⁶ MSCs/kg or 1.5 × 10 ⁶ MSCs/kg, depending on CRP level	• Equivalent volume of placebo will be administered	• Primary outcomes: Mortality at Day 28; Mortality at Days 60 and 90; Number of ventilator-free days [Time Frame: Randomization through Day 28]; Improvement in oxygenation [Time Frame: Randomization to Day 2, Day 4, Day 6, Day 14, Day 28]; SOFA score at Day 28.	Withdrawn (Replaced by a different protocol.)

(continued on next page)

Table 4 (Continued)

Title (year)	Study method	Population	Intervention	Comparator	Outcomes	Status
A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences' Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19 (2020)	• Randomized, Double-Blind, Placebo-Controlled Single-Center Clinical Trial	• 55 participants (all gender, > 18 years, high-risk potential exposure to COVID-19 job/no signs or symptoms of infection, agrees to the collection of venous blood per protocol, agrees to confirmational testing for SARS-CoV-2 before end of study.	• 5 intravenous infusions of 200 million cells/dose each. Infusions will occur at weeks 0, 2, 6, 10, and 14. • 5 intravenous infusions of 100 million cells/dose each. Infusions will occur at weeks 0, 2, 6, 10, and 14. • 5 intravenous infusions of 50 million cells/dose each. Infusions will occur at weeks 0, 2, 6, 10, and 14.	• 5 intravenous infusions of placebo infusions will occur at weeks 0, 2, 6, 10, and 14.	• Primary outcomes: Incidence of hospitalization for COVID-19 [Time Frame: week 0 through week 26]; Incidence of symptoms associated with COVID-19 [Time Frame: week 0 through week 26] • Secondary outcomes: Absence of upper/lower respiratory infection [Time Frame: weeks 0 through week 26]; Leukocyte differential [Time Frame: weeks 0, 6, 14, 26]; CRP [Time Frame: weeks 0, 6, 14, 26]; TNF alpha [Time Frame: weeks 0, 6, 14, 26]; IL-6 [Time Frame: weeks 0, 6, 14, 26]; IL-10 [Time Frame: weeks 0, 6, 14, 26]; Glucose [Time Frame: weeks 0, 6, 14, 26]; Ca [Time Frame: weeks 0, 6, 14, 26]; Albumin [Time Frame: weeks 0, 6, 14, 26]; Total protein [Time Frame: weeks 0, 6, 14, 26]; Na [Time Frame: weeks 0, 6, 14, 26]; Total carbon dioxide [Time Frame: weeks 0, 6, 14, 26]; K [Time Frame: weeks 0, 6, 14, 26]; Cr [Time Frame: weeks 0, 6, 14, 26]; BUN [Time Frame: weeks 0, 6, 14, 26]; Cr [Time Frame: weeks 0, 6, 14, 26]; AP [Time Frame: weeks 0, 6, 14, 26]; ALT [Time Frame: weeks 0, 6, 14, 26]; Total Bil [Time Frame: weeks 0, 6, 14, 26]; white blood cells [Time Frame: weeks 0, 6, 14, 26]; red blood cells [Time Frame: weeks 0, 6, 14, 26]; Hb [Time Frame: weeks 0, 6, 14, 26]; Ht [Time Frame: weeks 0, 6, 14, 26]; MCV [Time Frame: weeks 0, 6, 14, 26]; MCHb concentration [Time Frame: weeks 0, 6, 14, 26]; MCHb [Time Frame: weeks 0, 6, 14, 26]; red cell distribution width [Time Frame: weeks 0, 6, 14, 26]; neutro [Time Frame: weeks 0, 6, 14, 26]; lymphs [Time Frame: weeks 0, 6, 14, 26]; Eos [Time Frame: weeks 0, 6, 14, 26]; Baso [Time Frame: weeks 0, 6, 14, 26]; Absolute neutro [Time Frame: weeks 0, 6, 14, 26]; Absolute eos [Time Frame: weeks 0, 6, 14, 26]; Absolute baso [Time Frame: weeks 0, 6, 14, 26]; Immature granulocytes [Time Frame: weeks 0, 6, 14, 26]; Platelets [Time Frame: weeks 0, 6, 14, 26]; PTT [Time Frame: weeks 0, 6, 14, 26]; INR [Time Frame: weeks 0, 6, 14, 26]; PT [Time Frame: weeks 0, 6, 14, 26]; SF-36 [Time Frame: weeks 0, 6, 14, 26]; PHQ-9 [Time Frame: weeks 0, 6, 14, 26]	Completed
Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19 (2020)	• Phase I / II Clinical Trial, Multicenter, Randomized and Controlled, Safety and Efficacy study	• 26 participants (Age ≥18, Clinical diagnosis of Pneumonia, severe or critical, caused by COVID-19 infection. Life expectancy > 48 h. Commitment to use a contraceptive method of proven efficacy in both men and women during the duration of the clinical trial).	• Two doses of 80 million adipose-tissue derived mesenchymal stem cells	No intervention	• Primary outcomes: Safety of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Adverse Event Rate [Time Frame: 12 months]; Efficacy of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Survival Rate [Time Frame: 28 days]	Completed
Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19 (2020)	• Phase II Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study	• 53 participants (Men, and women, > 18 years of age inclusive). Patient is hospitalized due to suspected COVID-19 infection. Agrees to the collection of venous blood per protocol).	• 4 IV infusions of HB-adMSCs at 100 million cells/dose. HB-adMSC infusions will occur at day 0, 3, 7, and 10.	• 4 IV infusions of placebo (saline solution). Infusions will occur at day 0, 3, 7, and 10.	• Primary outcomes: IL-6, CRP, Oxygenation, TNF alpha, IL-10 [Time Frame: screening, day 0, 7, 10]; Return to room air (RTAA) [Time Frame: Day 0, 3, 7, 10, 28]. • Secondary outcomes: EKG qt interval, Leukocyte differential, Glucose, Ca, Albumin, Total protein, Na, Total carbon dioxide, K, Cl, BUN, Cr, AP, ALT, Total Bil, White blood cells, Red blood cells, Hb, Ht, MCV, MCHb, MCHC, Red cell distribution width, Neutro, Lymphs, Mono, Eos, Baso, Absolute neutro, Absolute lymphs, Absolute mono, Absolute eos, Absolute baso, Immature granulocytes, PTT, INR, NK cell surface anti gen (CD3-CD54 +), clinical lab evaluation of percentage of cells CD3- and CD54 + (%), CD4 + /CD8 + ratio Myoglobin, Troponin, Creatinine kinase MB, Serum ferritin [Time Frame: screening, day 0, 7, 10]; Adverse events [Time Frame: screening through day 28]; 7 point ordinal scale [Time Frame: screening, day 0, 3, 7, 10, 28]; >dimer [Time Frame: screening, day 0, 7, 10]; Chest X-Ray [Time Frame: Day 0, Day 28]; CT scan [Time Frame: Day 0, Day 28]; PCR test for SARS-CoV-2 [Time Frame: day 0, 3, 7, 10]	Terminated (No need to continue with vaccine available)
Study of Intravenous COVID-MSC for Treatment of COVID-19 – Induced Acute Respiratory Distress (2021)	• Phase II, Randomized, parallelly assignmented, quadruple blinded study	• 100 participants (Men, and women, > 18 years Laboratory-confirmed SARS-CoV-2 infection, Hospitalized with COVID-19-induced ARD or ARDS with a Pao2/FiO2 ≤300; Requires oxygen supplementation at Screening. Willing to follow contraception guidelines	• IV infusions of COVID-MSC (two vials or a total of ≈30 million cells) on Day 0, Day 2, and Day 4	• IV infusions of placebo (two vials) on Day 0, Day 2, and Day 4	• Primary outcomes: All-cause mortality rate at Day 28 [Time Frame: Baseline through Day 28]; • Secondary outcomes: All-cause mortality rate at Day 60 and Day 90 [Time Frame: Baseline through Day 28, Day 60 and Day 90]; Number of ventilator-free days through Day 28 [Time Frame: Baseline through Day 28]; Number of ICU days through Day 28 [Time Frame: Baseline through Day 28]; Change in clinical status [Time Frame: Baseline to Day 28]; Change in oxygenation [Time Frame: Baseline to Day 2, Day 4, Day 6, Day 14 and Day 28]	Recruiting

(continued on next page)

Table 4 (Continued)

Title (year)	Study method	Population	Intervention	Comparator	Outcomes	Status
Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 Syndrome (HBPCOVID02) (2021)	• Phase II, Randomized, Double-blinded, Single-center, Efficacy, and Safety Study	• 80 participants (Men, and women, 18–70 years, proof of Post COVID-19 Syndrome in their medical records, diagnosed with Chronic post-COVID-19 syndrome for at least twelve weeks before, one or more neurological symptoms, participants should not be pregnant or plan to become pregnant during study participation and six months after the last investigational product administration, If their sexual partners can become pregnant, male participants should use a method of contraception during study participation and for six months after the last administration of the experimental drug, The study participant is able and willing to comply with the requirements of this clinical trial.	• ASCs (Does not describe the dosage)	• Sterile Normal Saline	• Primary outcomes: Changes in Visual Analog Scale of Neurological Symptoms. - Extreme fatigue, Changes in Visual Analog Scale of Neurological Symptoms. - Brain fog, Changes in Visual Analog Scale of Neurological Symptoms. - Headache, Changes in Visual Analog Scale of Neurological Symptoms. - Sleep disturbances, Changes in Visual Analog Scale of Neurological Symptoms. - Loss of taste, Changes in Visual Analog Scale of Neurological Symptoms. - Loss of smell, Incidence of treatment-emergent Adverse Event (TEAEs), Incidence of treatment-emergent Serious Adverse Events (SAEs), AEs of special interest (serious or non-serious) - thromboembolic events, AEs of special interest (serious or non-serious) - thromboembolism of the extremities. [Time Frame: Baseline to Weeks 26]. Incidence and risk of AEs of special interest (serious or non-serious), including peripheral events defined as, thromboembolism of the extremities, AEs of special interest (serious or non-serious) - infections, Incidence and risk of AEs of special interest (serious or non-serious) - hypersensitivities, Changes in Laboratory values. - CBC, Changes in Laboratory values. - CMP, Changes in Laboratory values. - Coagulation Panel, Changes in Vital Signs. - Respiratory Rate (breaths per minute), Changes in Vital Signs. - Heart Rate (beats per minute), Changes in Vital Signs. - Body Temperature (Fahrenheit), Changes in Vital Signs. - Blood Pressure (mmHg), Changes in Weight in lb., Changes in Physical examination results. - General [Time Frame: Baseline to Weeks 26], Clinically significant changes in general physical examination results. Changes in Physical examination results. - Body Systems [Time Frame: Baseline to Weeks 26] • Secondary outcomes: Changes in Subject's energy - Fatigue Assessment form, Changes in Visual Analog Scale of non-Neurological Symptoms. - Dyspnea at rest, Changes in Visual Analog Scale of non - Neurological Symptoms. - Dyspnea with activity, Changes in Visual Analog Scale of non - Neurological Symptoms. - Cough, Changes in Visual Analog Scale of non - Neurological Symptoms. - Body aches, Changes in Visual Analog Scale of non-Neurological Symptoms. - Joint pain, Changes in Subject's quality of life - Short Form 36 Health Survey Questionnaire, Changes in Subject's level of depression - PHQ 9 scale. [Time Frame: Baseline to Weeks 26]	Recruiting
BAtLe Against COVID-19 Using Mesenchymal Stromal Cells (2020)	• Phase II Two-treatment, Randomized, Controlled, Multicenter Clinical Trial	• 80 participants (Men, women, 18–70 years, proof of Post COVID-19 Syndrome, participants should not be pregnant or plan to become pregnant during study participation and six months after the last investigational product administration, If their sexual partners can become pregnant, male participants should use a method of contraception during study participation and for six months after.	• Two serial doses of 1.5 million adipose-tissue derived mesenchymal stem cells per kg	• Regular respiratory distress treatment	• Primary Outcomes: Efficacy of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Survival Rate [Time Frame: 28 days]; Safety of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Adverse Event Rate [Time Frame: 6 months]	Suspended (lack of financial support)
Intermediate Size Expanded Access Protocol for the Treatment of Post-COVID-19 Syndrome (2021)	• Does not describe study method or phase	• Does not describe number of participants	• Route: Intravenous • Dose: 200 million autologous adipose derived mesenchymal stem cells.	• Does not describe if there is a control group	• Does not describe the outcomes	No longer available
Study to Evaluate the Efficacy and Safety of AstroStem-V in Treatment of COVID-19 Pneumonia (2020)	• Phase I/IIa, open label, single group assignment, Trial to Explore the Safety and Efficacy study	• 10 participants (19–80 years; diagnosed with pneumonia by radiologic examination, hospitalized for pneumonia caused by COVID-19 infection at screening, subject who has moderate COVID-19 disease, voluntarily participate in the clinical trial with written informed consent	• ASCs (Does not describe the dosage)	None	• Primary outcomes: Treatment related adverse events [Time Frame: From baseline to Week 12]; Number of subjects with treatment related abnormal variation of vital signs, physical examination and laboratory test values [Time Frame: From baseline to Week 12] • Secondary outcomes: Oxygenation index (PaO2/FiO2 ratio) [Time Frame: From baseline to Week 12]; Mortality rate [Time Frame: Week 4, Week 8, and Week 12]; Ventilator treatment status [Time Frame: From Week 1 to Week 12]; Improvement of pneumonia [Time Frame: From baseline to Week 12]; SOFA [Time Frame: From baseline to Week 12]; 2019 nCoV nucleic acid test [Time Frame: From baseline to Week 12].	Not yet recruiting
Cx611–0204 SEPCELL Study (2020)	• Phase Ib/IIa, randomised, double-blind, multicentre trial.	• 84 patients with 18–80 years; body weight 50–100 kg; clinical diagnosis of sCABP (within ≤21 past days) + radiographic findings; ICU management, IMV or treatment with vasopressors for at least 2 h, negative pregnancy treatment.	• Two central line infusions of Cx611 administered within 3 days (on days 1 and 3) at a dose of 160 million cells each • Does not describe stem cell (CD) markers • Follow up: up to day 730	• Will receive SoC therapy according to local guidelines plus two intravenous central line infusions of Ringer Lactate.	• Primary outcomes: safety profile and potential immunological host responses against the administered cells during the follow-up period. • Secondary outcomes: explore the clinical efficacy of Cx611 in terms of a reduction of the duration of mechanical ventilation and/or the need for vasopressors and/or improved survival and/or clinical cure of the sCABP, as well as other efficacy-related endpoints.	Completed

SVF, Stromal Vascular Fraction; PRP, Platelet Rich Plasma; BMMC, Bone Marrow Mononuclear Cells; ASCs, Adipose-derived Stem Cell; COPD, Chronic Obstructive Pulmonary Disease; CRP, C-Reactive Protein; Pro-BNP, Pro-type B Natriuretic peptide; BI, Bilirubin; Cr, Creatinine; AEs, Adverse Effects; SAEs, Severe Adverse Effects; SOFA, Sequential Organ Failure Assessment; IV, Intravenously; CCO, Corticosteroids; ARDS, Acute Respiratory Distress Syndrome; 6MWD, 6-Minute Walk Distance; AP, Alkaline Phosphatase; ALT, Alanine Aminotransferase; AST, Aspartate Aminotransferase; K, Potassium; Hb, Hemoglobin; Ht, Hematocrit; MCV, Mean Corpuscular Volume; MCHb, Mean Corpuscular Hemoglobin; Eos, Eosinophils; Neutro, Neutrophils; Lymphs, Lymphocytes; Mono, Monocytes; Baso, Basophils; Ca, Calcium; Na, Sodium; Cl, Chloride; PTT, Prothrombin Time; SF-36, Short-Form 36 Health Survey.

This study has among its limitations the selection bias, inherent to any non-systematic review; the limitation of most studies to interventions in the early inflammatory phase, offering better support for acute exacerbations to the detriment of its real applicability in the chronic fibrotic phase of the disease; the non-standardization of treatment time and dosage; as well as the lack of methodological rigor of some evidence included by not describing: their MSC surface markers, the parameters used in the analysis of the studies, nor the presence or absence of adverse effects.

Databases used in the present article are the main ones used in similar studies and allow contact with the vast amount of available literature on the subject. However, EMBASE database could not be included since CAPES periodicals does not provide its access through CAFE space. In addition, as it is a topic of recent emergence in the literature and, consequently, has an insufficient amount of clinical evidence for analysis, this study includes narrative reviews and preclinical studies to provide a summary of the currently available evidence on the topic, however, these study types have low-level certainty and high-level biases.

Finally, although the revised clinical data suggests optimism in the applicability of ASCs in other immunoinflammatory diseases [5,6,14–17,20–23,28–31,37–43] the little clinical evidence available about the effectiveness of this treatment lacks standardization, making it difficult to extrapolate its results. Therefore, further studies are needed to be focused on the elaboration of a consensus on the methods of collection of ASCs, the ideal dosage schedule, the most effective time and route of administration, as well as on the definition of indications for the administration of ASCs in cases of COVID-19 for conducting clinical trials soon.

Conclusion

The revised clinical data suggests optimism in the applicability of ASCs in other immunoinflammatory diseases and in severe COVID-19 ARDS. However, further studies are needed to develop a consensus on the methods of collection of ASCs, the ideal dosage schedule, the most effective time and route of administration, as well as on the definition of indications for the administration of ASCs in cases of COVID-19 for conducting clinical trials in near future.

Authors' contributions

Bruna Benigna Sales Armstrong: Collected the data, performed the analysis and wrote the paper.

Juan Carlos Montano Pedroso: Supervised the project, revised it critically for important intellectual content and made a substantial contribution to the interpretation of data.

José da Conceição Carvalho Jr.: Supervised the project, revised it critically for important intellectual content and made a substantial contribution to the interpretation of data.

Lydia Masako Ferreira: Conceived and designed the review, supervised the project, revised it critically for important intellectual content, and gave the final approval of the version to be published. All authors reviewed the results and approved the final version of the manuscript

Financial support and sponsorship

None.

Declaration of Competing Interest

The authors declare no conflicts of interest.

Acknowledgement

None.

References

- Cruz FF, Rocco PRM. The potential of mesenchymal stem cell therapy for chronic lung disease. *Expert Rev Respir Med* 2020;14(1):31–9.
- World Health Organization. Emergency situational updates. coronavirus disease (COVID-19) Weekly epidemiological update - 2 March 2021.
- Liu S, Peng D, Qiu H, Yang K, Fu Z, Zou L. Mesenchymal stem cells as a potential therapy for COVID-19. *Stem Cell Res Ther* 2020;11(1):169.
- Lu L, Zhong W, Bian Z, Li Z, Zhang K, Liang B, et al. A comparison of mortality-related risk factors of COVID-19, SARS, and MERS: a systematic review and meta-analysis. *J Infect* 2020;81(4):e18–25.
- Behnke J, Kremer S, Shahzad T, Chao C-M, Böttcher-Friebertshäuser E, Morty RE, et al. MSC Based Therapies—New Perspectives for the Injured Lung. *J Clin Med* 2020;9(3):682.
- Yen BL, Yen M, Wang L, Liu K, Sytwu H. Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: gleaming insights for possible use in COVID-19. *Stem Cells Transl Med* 2020;9(10):1163–73.
- Geiger S, Hirsch D, Hermann FG. Cell therapy for lung disease. *Eur Respir Rev* 2017;26(144):170044.
- Schweitzer KS, Johnstone BH, Garrison J, Rush NI, Cooper S, Traktuev DO, et al. Adipose stem cell treatment in mice attenuates lung and systemic injury induced by cigarette smoking. *Am J Respir Crit Care Med* 2011;183(2):215–25.
- NIH. Clinical Trial Database. 2020. Disponível em: <https://www.clinicaltrials.gov/ct2/results?recrs=&cond=Pulmonary+Disease&term=mesenchymal+stem+cells&cntry=&state=&city=&dist=>
- NIH. Clinical Trial Database. 2020. Disponível em: <https://www.clinicaltrials.gov/ct2/results?recrs=&cond=COVID-1919&term=mesenchymal+stem+cells&cntry=&state=&city=&dist=>
- Fikry EM, Safar MM, Hasan WA, Fawzy HM, El-Denshary E-E-DS. Bone Marrow and Adipose-Derived Mesenchymal Stem Cells Alleviate Methotrexate-Induced Pulmonary Fibrosis in Rat: comparison with Dexamethasone. *J Biochem Mol Toxicol* 2015;29(7):321–9.
- Wecht S, Rojas M. Mesenchymal stem cells in the treatment of chronic lung disease: mesenchymal stem cells and lung injury. *Respirology* 2016;21(8):1366–75.
- Sour N, Thébaud B. Mesenchymal Stromal Cells in Animal Bleomycin Pulmonary Fibrosis Models: a systematic review: mSCs in animal bleomycin pulmonary fibrosis models. *Stem Cells Transl Med* 2015;4(12):1500–10.
- Sadeghian Chaleshtori S, Mokhber Dezfouli MR, Jabbari Fakhr M. Mesenchymal stem/stromal cells: the therapeutic effects in animal models of acute pulmonary diseases. *Respir Res* 2020;21(1):110.
- Shi L, Wang L, Xu R, Zhang C, Xie Y, Liu K, Li T, Hu W, Zhen C, Wang FS. Mesenchymal stem cell therapy for severe COVID-19. *Signal Transduct Target Ther* 2021;6(1):339.
- Harrell CR, Sadikot R, Pascual J, Fellabaum C, Jankovic MG, Jovicic N, et al. Mesenchymal Stem Cell-Based Therapy of Inflammatory Lung Diseases: current Understanding and Future Perspectives. *Stem Cells Int* 2019;2019:1–14.
- Xiao K, Hou F, Huang X, Li B, Qian ZR, Xie L. Mesenchymal stem cells: current clinical progress in ARDS and COVID-19. *Stem Cell Res Ther* 2020;11(1):305.
- Chen S, Cui G, Peng C, Lavin MF, Sun X, Zhang E, et al. Transplantation of adipose-derived mesenchymal stem cells attenuates pulmonary fibrosis of silicosis via anti-inflammatory and anti-apoptosis effects in mice. *Stem Cell Res Ther* 2018;9(1):110.
- Dong L-H, Jiang Y-Y, Liu Y-J, Cui S, Xia C-C, Qu C, et al. The anti-fibrotic effects of mesenchymal stem cells on irradiated lungs via stimulating endogenous secretion of HGF and PGE2. *Sci Rep* 2015;5(1):8713.
- Cho K-S, Park M-K, Kang S-A, Park H-Y, Hong S-L, Park H-K, et al. Adipose-derived stem cells ameliorate allergic airway inflammation by inducing regulatory T cells in a mouse model of asthma. *Mediators Inflamm* 2014;2014:436476.
- Felix RG, Bovolenta ALC, Cotrim OS, Leão P dos S, Capelozzi VL. Adipose-derived stem cells and adipose-derived stem cell—conditioned medium modulate in situ imbalance between collagen I— and collagen V—mediated IL-17 immune response recovering bleomycin pulmonary fibrosis. *Histol Histopathol* 2020;35(3):289–301.
- Radwan SM, Ghoneim D, Salem M, Saeed M, Saleh Y, Elhamy M, et al. Adipose tissue—derived mesenchymal stem cells protect against amiodarone-induced lung injury in mice. *Appl Biochem Biotechnol* 2020;191(3):1027–41.
- Reddy M, Fonseca L, Gowda S, Chougule B, Hari A, Totey S. Human adipose-derived mesenchymal stem cells attenuate early stage of bleomycin induced pulmonary fibrosis: comparison with pirfenidone. *Int J Stem Cells* 2016;9(2):192–206.
- Latterre PF, Sánchez-García M, van der Poll T, de la Rosa O, Cadogan KA, Lombardo E, et al. A phase Ib/IIa, randomised, double-blind, multicentre trial to assess the safety and efficacy of expanded Cx611 allogeneic adipose-derived stem cells (eASCs) for the treatment of patients with community-acquired bacterial pneumonia admitted to the intensive care unit. *BMC Pulm Med* 2020;20(1):309.
- Mao Y-X, Xu J-F, Seeley EJ, Tang X-D, Xu L-L, Zhu Y-G, et al. Adipose tissue-derived mesenchymal stem cells attenuate pulmonary infection caused by pseudomonas aeruginosa via inhibiting overproduction of prostaglandin E2: adipose tissue-derived mesenchymal stem cells attenuate. *Stem Cells* 2015;33(7):2331–42.
- Sánchez-Guijo F, García-Arranz M, López-Parra M, Monedero P, Mata-Martínez C, Santos A, et al. Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study. *EClinicalMedicine* 2020;25:100454.
- Feizpour A, Boskabady MH, Ghorbani A. Adipose-derived stromal cell therapy affects lung inflammation and tracheal responsiveness in guinea pig model of COPD. *Di YP, organizador. PLoS ONE* 2014;9(10):e108974.
- Gao P, Yang X, Mungur L, Kambo S, Wen Q. Adipose tissue-derived stem cells attenuate acute lung injury through eNOS and eNOS-derived NO. *Int J Mol Med* 2013;31(6):1313–8.

29. Pedrazza L, Cunha AA, Luft C, Nunes NK, Schmitz F, Gassen RB, et al. Mesenchymal stem cells improves survival in LPS-induced acute lung injury acting through inhibition of NETs formation. *J Cell Physiol* 2017;**232**(12):3552–64.
30. Qin H, Zhao A. Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics. *Protein Cell* 2020;**11**(10):707–22.
31. Zheng G, Huang L, Tong H, Shu Q, Hu Y, Ge M, et al. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. *Respir Res* 2014;**15**(1):39.
32. Antoniou K, Karagiannis K, Tsitoura E, Bibaki E, Lasithiotaki I, Prokhou A, et al. Clinical applications of mesenchymal stem cells in chronic lung diseases (Review). *Biomed Rep* 2018;**8**(4):314–8.
33. Barczyk M, Schmidt M, Mattoli S. Stem Cell-Based Therapy in Idiopathic Pulmonary Fibrosis. *Stem Cell Rev Rep* 2015;**11**(4):598–620.
34. Lee SH, Lee EJ, Lee SY, Kim JH, Shim JJ, Shin C, et al. The effect of adipose stem cell therapy on pulmonary fibrosis induced by repetitive intratracheal bleomycin in mice. *Exp Lung Res* 2014;**40**(3):117–25.
35. Ntoliou P, Steiropoulos P, Karpathiou G, Anevavis S, Karampitsakos T, Bouros E, et al. Cell therapy for idiopathic pulmonary fibrosis: rationale and progress to date. *BioDrugs* 2020;**34**(5):543–56.
36. Tashiro J, Elliot SJ, Gerth DJ, Xia X, Pereira-Simon S, Choi R, et al. Therapeutic benefits of young, but not old, adipose-derived mesenchymal stem cells in a chronic mouse model of bleomycin-induced pulmonary fibrosis. *Transl Res* 2015;**166**(6):554–67.
37. Perlee D, de Vos AF, Scicluna BP, Maag A, Mancheño P, de la Rosa O, et al. Role of tissue factor in the procoagulant and antibacterial effects of human adipose-derived mesenchymal stem cells during pneumosepsis in mice. *Stem Cell Res Ther* 2019;**10**(1):286.. a.
38. Perlee D, Vos AF, Scicluna BP, Mancheño P, Rosa O, Dalemans W, et al. Human adipose-derived mesenchymal stem cells modify lung immunity and improve antibacterial defense in pneumosepsis caused by *Klebsiella Pneumoniae*. *Stem Cells Transl Med* 2019. b;MSC.18-0260.
39. Jiang X, Jiang X, Qu C, Chang P, Zhang C, Qu Y, et al. Intravenous delivery of adipose-derived mesenchymal stromal cells attenuates acute radiation-induced lung injury in mice. *Cytotherapy* 2015;**17**(5):560–70.
40. Gentile P, Sterodimas A. Adipose-derived stromal stem cells (ASCs) as a new regenerative immediate therapy combating coronavirus (COVID-19) -induced pneumonia. *Expert Opin Biol Ther* 2020;**20**(7):711–6.
41. Zandoni M, Cortesi M, Zamagni A, Tesi A. The role of mesenchymal stem cells in radiation-induced lung fibrosis. *Int J Mol Sci* 2019;**20**(16):3876.
42. Kim Y-S, Kim J-Y, Shin D-M, Huh JW, Lee SW, Oh Y-M. Tracking Intravenous Adipose-Derived Mesenchymal Stem Cells in a Model of Elastase-Induced Emphysema. *Tuberc Respir Dis (Seoul)* 2014;**77**(3):116.
43. Rogers CJ, Harman RJ, Bunnell BA, Schreiber MA, Xiang C, Wang F-S, et al. Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients. *J Transl Med* 2020;**18**(1):203.
44. Stabler CT, Lecht S, Lazarovici P, Lelkes PI. Mesenchymal stem cells for therapeutic applications in pulmonary medicine. *Br. Med. Bull.* 2015;**115**(1):45–56.
45. Trzil JE, Masseau I, Webb TL, Chang C-H, Dodam JR, Cohn LA, et al. Long-term evaluation of mesenchymal stem cell therapy in a feline model of chronic allergic asthma. *Clin Exp Allergy* 2014;**44**(12):1546–57.